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Abstract 
 
Introduction A cholesteatoma is a mass of keratinizing epithelium in 
the middle ear. It is a rare disorder, associated with significant 
morbidity, especially deafness. There is little evidence for Mendelian 
inheritance, but an  original observation by the author of affected 
families in Norfolk, including individuals with bilateral disease, 
suggests a genetic component for its aetiology.  
 
Methods  A systematic literature review to identify  studies about the 
genetics of cholesteatoma  has been performed and a  biobank for 
subsequent whole exome sequencing  studies of familial disease has 
been established.  A pilot sequencing study to identify candidate 
variants that segregate with the disease phenotype, using 
NimbleGen library construction and exome capture and the Illumina 
HiSeq4000 platform, has been completed. 
 
Results The  literature review identified several case-series with 
multiply-affected families and associations with congenital 
malformation syndromes.  
 
DNA and clinical data has been collected from 66 participants from 13 
multiply affected Norfolk families. The pilot whole exome sequencing 
[WES] study of 16 participants from four  families identified 95,437 
variants. In one family all five recruited individuals have been 
sequenced. Variant filtering, using pedigree analysis, has identified 
several mutations of potential significance.  
 
Conclusion A systematic review has been completed and a unique 
biobank to explore the  genetics of cholesteatoma is established  A 
WES strategy and bioinformatics pipeline have been developed in the 
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pilot study and preliminary filtering has identified candidate variants 
that could have an impact on relevant biological pathways. There are 
no other published descriptions of a WES strategy to investigate the 
genetics of familial cholesteatoma. The potential impact of  an 
understanding  of the genetic basis of cholesteatoma is discussed. 
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Chapter 1 The Genetics of Cholesteatoma 
 
An introduction to an MD Thesis by Peter Prinsley FRCS  
Introduction 
 
The old Norfolk and Norwich Hospital is mostly demolished. The remains of 
the Victorian buildings have become expensive flats and there is a brand 
new Norfolk and Norwich University Hospital outside the city. I started work 
at the old hospital as a Consultant ENT Surgeon, with what the BMJ had 
advertised as a “responsibility to provide an otology service to the people of 
Norfolk”, in the summer  of 1996. 
 
In one of my first clinics, a mother walked in with three children, identical 
twin sisters and an older brother. A note from the GP had asked me to see 
the twins about their ears.  
 
“What is the matter with the girls’ ears?” I asked.  
 
“Cholesteatoma” says mum. 
 
“How on earth do you know that?” I said. 
 
“Well, their brother here had the same and he’s had his ear operated by 
another doctor”. 
 
Sure enough, one of the girls had pus discharging from one ear and her sister 
was discharging pus from both ears. Mum was quite correct. I couldn’t resist 
looking into their brother’s ear and observed a beautifully healed mastoid 
cavity operated some years earlier by my colleague. Four cholesteatomas in 
three  siblings! 
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A little enquiry revealed a cousin with a cholesteatoma and an account of a 
great uncle who had died as a small child in the 1920s as a result of an ear 
infection. In the family pedigree drawings the solid symbols represent 
affected individuals and the asterix refers to a recruit to the Genetics of 
Cholesteatoma  Project. 
 
 
 
 
Figure 1-1 The twins’ extended family. There is an  affected cousin and a family story that a great 
uncle had  died in childhood from an ear infection. 
 
 
Cholesteatoma, which is a chronic destructive disease of the ear causing 
discharge and deafness, is not traditionally considered to be a genetic 
disorder but I could not fail to notice that there was something rather 
unusual about this family. 
 
Before too long several more families came to light. One day, during a lull in 
the clinic, a nurse called K, asked me to look in her ear. 
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Figure 1-2 Endoscopic view of K’s ear 
K had been previously operated for a perforated ear drum but felt something 
blocking her ear. There was an obvious cholesteatoma “pearl” behind an 
intact drum. It turned out there were plenty of people in K’s family with 
cholesteatoma. 
 
 
 
Figure 1-3 K’s family. K and her sister C both have bilateral cholesteatoma and other family members 
who are affected are shown. 
 
Cholesteatoma pearl 
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Over the next decade a substantial number of families in which there were 
two or more affected individuals were collected and this was published as a 
report in in 2009 (Prinsley, 2009a). 
 
One of the most remarkable families was D’s family [Figure 1.4]. 
 
 
 
Figure 1-4 D’s family. Missing from the diagram is III-I’s daughter  who has been subsequently 
diagnosed with a cholesteatoma. 
 
This introduction presents some observations about cholesteatoma based 
on my own clinical experience and uses data from the Norfolk patients under 
my care recorded in the web based international otology audit. The Norfolk 
Genetics of Cholesteatoma Project is a scientific enquiry into the possible 
genetic basis of the condition based on these familial observations. 
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The ear drum 
 
 
 
Figure 1-5 Normal ear drum. Photograph of a normal human right ear drum showing the malleus 
handle and the triangle of light which is created by the concavity of the anterior drum and is sign of a 
healthy ear drum. 
 
The ear drum consists of modified skin which forms the lateral aspect of the 
air-filled  middle ear. It is part of an exquisite biological mechanism which 
has evolved to convert mechanical energy of sound waves into electrical 
signals within the cochlea of the inner ear via a delicate chain of tiny bones 
called the malleus, the incus and the stapes [figure1-6]. In health, the middle 
ear is filled with gas at atmospheric pressure which equilibrates with the 
partial gas pressures of the surrounding blood and is connected 
intermittently to the air of the nasopharynx via the Eustachian tube. 
Posteriorly the middle ear space is contiguous with a complex of open spaces 
within the mastoid bone termed the “air cells”.  
 
Malleus handle 
Triangle of 
light  
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Figure 1-6 In this patient the outer attic wall or scutum has been resected to reveal the ossicular 
chain which has been preserved. 
 
 
What is a cholesteatoma 
Cholesteatoma is a chronic disorder of the ear which is an important cause 
of acquired deafness in children and adults. It occurs throughout the world 
and can only definitively be treated by complex microsurgery to try and 
remove the disease from the ear. There are over 7000 operations for this 
disease in the UK NHS each year and the majority of patients suffer lifelong 
hearing loss as a consequence of the disease and the surgery. Perhaps a 
million people are afflicted annually worldwide. 
 
Pathologically  cholesteatoma is a well-demarcated non neoplastic lesion in 
the temporal bone that arises from an abnormal growth of keratinizing 
squamous epithelium (Semaan and Megerian, 2006) (Bhutta et al., 2011). 
 
Incus 
Malleus 
Stapes 
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Abnormality of drum skin migration and desquamation is thought to 
predispose to the accumulation of cholesteatoma within the middle ear 
which may be locally invasive and capable of causing bone destruction. 
 
A patient with a cholesteatoma might notice a blocked sensation in the ear 
and complain of a painless foul smelling discharge. The diagnosis is made on 
otoscopy which reveals a number of different characteristic drum 
abnormalities. 
 
 
 
Figure 1-7. An attic crust and the  audiogram showing a hearing difference of 20 to 30 dB between 
the right and left ear. 
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The elderly patient in figure 1-7 has an “attic crust”. When this was removed 
a collection of white squamous debris was observed to have accumulated 
within a drum defect and to have filled the middle ear. There was 
destruction of the incus long process and conductive deafness. 
 
Operative photographs taken through a 30 degree endoscope of a 38 y old 
patient with a history of deafness and otorrhoea demonstrate the extent of 
the disease [Figure 1-8]. 
 
 
 
 
 
 
Attic defect 
revealing the neck of 
a cholesteatoma 
Extent of the 
cholesteatoma 
exposed by bone 
removal 
Figure 1-8 Operative photographs showing the extent of the cholesteatoma 
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The first picture shows the view at the start of the operation and the second 
picture shows the extent of the cholesteatoma in the mastoid as the 
overlying bone has been removed with an operating drill. 
 
Many patients like these present to the ENT clinics and a great deal of my 
own work as an otologist in Norfolk has been spent trying to help people 
with the condition. The only curative treatment for cholesteatoma is surgical 
excision, although by no means all patients with the condition are operated. 
Hospital Episode Statistics from NHS Digital show that about 7000 people 
are admitted for surgical treatment of middle ear cholesteatoma [STMEC] 
annually in England and Wales. Personal data shows approximately 33 
patients admitted annually for STMEC in the Norfolk and Norwich and James 
Paget University Hospitals. Surgical data for cholesteatoma has been 
prospectively collected for 10 years between 2007 and 2017 using the 
International Otology Database (www.ear-audit.net) (Van Rompaey et al., 
2010). 
 
Cholesteatoma is usually unilateral. In my own operated patients, between 
2007 and 2017, 293 patients underwent 332 operations for middle ear 
cholesteatoma and 17 of the patients had bilateral surgery which 5.8%. The 
true incidence of bilateral disease is higher than this because some patients 
with cholesteatoma were not operated and some patients had the first ear 
operated elsewhere and are not included in the audit. 
 
Cholesteatoma progresses to bone destruction and deafness or runs an 
indolent course with little in the way of symptoms, and therefore requires 
no treatment other than periodic observation and cleaning of the ear in the 
  
 
 
25 
out patients department.  Sometimes a cholesteatoma will expel itself into 
the ear canal as the bone margins of the tympanic membrane are eroded to 
create an appearance referred to as an auto-mastoidectomy. 
 
Symptoms of cholesteatoma 
 
Figure 1-9 shows that the predominating presenting complaints are 
otorrhoea and hearing loss in the 332 operations recorded in the audit of 
the Norfolk patients treated for cholesteatoma. 
 
 
 
Figure 1-9. Chart showing the predominating presenting symptoms in cholesteatoma. 
 
 
Cholesteatoma is associated with osteolytic bone reabsorption and 
superimposed bacterial infection.  Erosion of the ossicular bones, most often 
of the long process of the incus results in a conductive deafness. 
 
Hearing loss 
45%
Otorrhoea
51%
Tinnitus
1%
Vertigo
1%
Otalgia
2%
Facial palsy
0%
Symptoms of patients with unilateral cholesteatoma
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The audit of 293 patients operated for cholesteatoma over 10 years in 
Norfolk recorded ossicular erosion in 67.4% of unilateral cases and 83.3% of 
bilateral cases, with incus erosion in 56.9% of unilateral cases and 80.6% of 
bilateral cases. This is the main cause of the conductive deafness in 
cholesteatoma. 
 
The average presenting conductive element of hearing loss attributed to the 
cholesteatoma was approximately 20dB. In table 1-1, this is the difference 
between the operated and non-operated ear in the unilateral cases. The 
bilateral cases in the chart show bilateral hearing loss. Complete 
disconnection of the ossicular chain results in a 60dB air bone gap but if the 
disconnection is partial or the cholesteatoma itself acts as a conducting 
mechanism to the stapes superstructure or footplate then the hearing is 
better. This is called “hearing through disease”. 
 
 
 
Table 1-1. Table to show the presenting dB  hearing loss  in the unilateral and bilateral cases. 
 
There are numerous reports of personal and institutional series of hearing 
results for cholesteatoma surgery. There is bias in the sense that experts are 
more likely to report than others. Children are reported as having less good 
hearing results.   
 
Ossicular damage correlates with hearing loss and revision cases seem to do 
worse in keeping with the Norfolk series. There are  differences between the 
Pure tone Audiogram  Unilateral Bilateral p Value [Student T – Test ] 
Mean Air-Bone gap – Operated 
Ear  
27.5 28.7 0.518 
Mean Air-Bone gap - Non-
operated ear  
7.17 21.2 0.005 
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unilateral and bilateral operative findings, perhaps suggesting that patients 
who have bilateral cholesteatoma have a constitutional factors predisposing 
to more aggressive disease. The p value needs to be interpreted with caution 
however in the absence of a Bonferroni adjustment. 
 
 
 
Table 1-2. Table to show the operative findings of patients with unilateral and bilateral 
cholesteatoma. 
 
 
Tympano-mastoidectomy is often successful in removing cholesteatoma but 
the restoration of hearing, even with the use of ossicular prostheses, is less 
assured. Only 60-70% of patients with cholesteatoma will recover functional 
hearing after tympano-mastoidectomy, and hearing is a major determinant 
of quality of life after such surgery (Nadol et al., 2000, Louw, 2013). 
 
Erosion of the cochlea or labyrinth results in a sensorineural deafness.  
Conductive deafness also results from surgery to treat cholesteatoma if it is 
necessary to remove ossicular bones, and in 2.7% of cases cochlear deafness 
as a consequence of bone erosion of the inner ear (Prinsley, 2013). Loss of 
Operative Findings Unilateral [%] Bilateral [%] p Value 
Anterior retraction pocket 5.1 5.5 0.572 
Posterior retraction pocket 18.5 30.6 0.015 
Attic Retraction 23.2 27.8 0.169 
Sinus Tympani Cholesteatoma 18.5 19.4 0.519 
Antrum Cholesteatoma 29.3 30.6 0.509 
Attic Cholesteatoma 69.6 80.6 0.112 
Mastoid Air cell cholesteatoma 19.2 27.8 0.047 
Ossicle Erosion 67.4 83.3 0.035 
Erosion of Incus 56.9 80.6 0.006 
Erosion of Malleus 15.2 18.9 0.327 
Erosion of Stapes 21.7 16.7 0.324 
Erosion of more than one 
ossicle 
27.2 30.6 0.401 
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bone overlying the vestibular fluid chambers of the inner ear, most 
commonly the lateral semicircular canal, results in vertigo. Gentle pressure 
of a finger in the ear canal displaces cholesteatoma overlying the labyrinth 
and causes dizziness and nystagmus. This is called a positive fistula sign. Such 
erosion may be well seen on axial CT scans as in Figure 1-10 and reported by 
the author (Prinsley, 2013). A loud sound may induce vertigo as a result of 
displacement of the fluid in areas of exposed membranous labyrinth known 
as Tullio phenomenon. 
 
 
 
Figure 1-10. Axial CT scan showing labyrinthine fistulas. 
This CT scan is taken is from a female patient of 83 years. There was a history 
previous cholesteatoma surgery on the right side with hearing loss. The scan 
shows a large clean cavity with an eroded labyrinth on the right side and a 
cholesteatoma on the left side with erosion of the lateral semicircular canal. 
 
Erosion of the temporal bone may progress to cause intracranial disease 
[Figure 1.11]. Oscar Wilde probably succumbed to this condition.  Although 
there is controversy, Robins and Sellars suggest that he died of encephalitic 
meningitis secondary to chronic ear suppuration, most likely cholesteatoma 
(Robins and Sellars, 2000). There is  a sad irony in the fact that Oscar Wilde’s 
father was Sir William Wilde, one  of the first and one of  the most celebrated 
ear surgeons in Ireland. 
 
Erosion of the 
lateral semicircular 
canal both sides 
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Figure 1-11. The author performed a mastoidectomy on this patient who had been treated at a 
regional neurosurgical centre for cerebral abscess. 
The Cause of Cholesteatoma 
 
The cause of this disease, so relentlessly destructive of the anatomy and 
function of the ear, is elusive. The epidemiology and pathogenesis of the 
condition are the subject of separate chapters in this thesis. 
 
Familial clustering , or the aggregation of a certain biological trait within a 
family, which has been observed in the patients reported in this study, may 
be environmental or genetic in origin. Some of the families reported here 
have no doubt shared “environments” but the  multi- generational family 
trees presented  for this rare disorder is compelling for a consideration of  
genetic factors and the observation of familial clustering is one of the first 
lines of evidence that a disease may have a genetic eitiology. 
 
Chronic otitis media in childhood predisposes to development of 
cholesteatoma (Djurhuus et al., 2015a) , but only a small proportion of those 
with chronic otitis media will develop cholesteatoma.  Animal models 
confirm the role of chronic mucosal inflammation in inducing cholesteatoma 
Temporal lobe abscess 
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(Huang et al., 1988, Vassalli et al., 1988, Masaki et al., 1989), but have also 
failed to illuminate how or why this occurs. There is mounting evidence that 
predisposition to cholesteatoma has a genetic basis.  Despite this being a 
rare disorder with an incidence of 1:10,000 per year, those who develop 
cholesteatoma have at least a 5% chance of developing disease in the 
contralateral ear.  In addition to my own report, others have described 
familial clustering of cholesteatoma (Prinsley, 2009a, Podoshin et al., 
1986b).  Because cholesteatoma is rare, perhaps genetic predisposition is 
determined by only a handful of genes, making it a polygenic rather than 
multigenic disorder.   
The Genetics of Cholesteatoma Project 
 
The pilot project presented in this thesis developed from the original 
observation about familial cholesteatoma 22 years ago. The science of 
genetics has advanced at an astonishing pace since then. In 2000, the draft 
sequence of the Human Genome Project was announced. It has become 
feasible to search for a possible genetic basis of cholesteatoma and the cost 
and speed of DNA sequencing are now at the point where this is practical. 
 
In the intervening two decades much has also changed in Norwich. There is 
a new Medical School with an Academic Department of Genetics.  My former 
trainee has returned as a Consultant colleague and has been appointed as 
Professor of ENT Surgery. The Earlham Institute for Genome Analysis has 
sprung up next to the new hospital and all the resources are now present in 
Norfolk for such an enterprise. 
 
A research team has assembled to identify genetic pathways predisposing 
to cholesteatoma. The study of families in which cholesteatoma is 
segregating involves genome sequencing coupled to a linkage analysis of 
DNA collected from affected and non-affected individuals.  In conjunction 
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with pedigree mapping, there is a unique opportunity to identify genetic 
polymorphisms associated with the formation of cholesteatoma, and by 
using multiple affected families, to identify recurrent pathways or genes by 
this method. 
 
 
Research Team and Funding 
 
Peter Prinsley, BMed Sci, MB ChB, FRCS Ed , FRCS Eng   
Consultant ENT Surgeon at The James Paget and Norfolk and Norwich 
University Hospitals, Norfolk UK. 
 
Barbara Jennings, PhD  
Senior Lecturer in Molecular Medicine, Norwich Medical School, Norfolk UK. 
 
Carl Philpott,  MD FRCS Orl 
Professor of ENT Surgery, Norwich Medical School and Consultant ENT 
Surgeon, James Paget University Hospital, Norfolk UK. 
 
Mahmood Bhutta , D Phil, FRCS Orl 
Consultant ENT Surgeon, Brighton, Sussex UK. 
 
Gavin Willis ,PhD  
Principal Clinical Scientist, Norfolk and Norwich University Hospital, Norfolk 
UK. 
 
Jane Woods, RN,  
Research Nurse, James Paget University Hospital, Norfolk UK. 
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The project has been approved by the Regional Research Ethics Committee 
and has been adopted by the NIHR Portfolio. The Norfolk families described 
above have been enrolled in this study in the early part of 2017 and the 
project was opened to recruitment around the UK in July 2017  to recruit 
families in which there are two or more affected cholesteatoma patients. 
 
 
 
 
Grants applications have resulted in the following funds being obtained for 
the pilot study: 
 
Royal College of Surgeons of England Modi Pump Priming Grant: £5000,  
 
Rosetrees Trust: £20,000,  
 
Bernice Bibby Fund:  £10,000. 
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Chapter 2 The Surgical Pathology of Cholesteatoma 
 
A case report of a child with bilateral cholesteatoma with observations on 
surgical pathology and theories of causation. 
 
Introduction 
 
Cholesteatoma is not a good name since there is neither cholesterol nor 
neoplasia and the name should really be changed. The first use of the term 
is attributed to the German physiologist Johannes Muller in 1838 who 
described a pearly fatty tumour of the ear (Olszewska et al., 2004). Eroding 
keratinocyst of the ear would be a better term. Joseph Toynbee, who is 
widely regarded as the father of British otology, and who was the first 
surgeon to be described as an aural surgeon did not use the term at all in his 
famous book Diseases of the Ear published in 1860 (Toynbee, 1860). Many 
patients died as a result of untreatable ear infections at this time and his 
book contains a number of detailed accounts of patients succumbing to the 
intracranial infections which resulted from what were described as bone 
replaced by a “soft cheesy mass” which must have been cholesteatoma.  
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Figure 2-1 Front piece from Joseph Toynbee 1860. 
 
The disease is characterized by an accumulation of keratinizing squamous 
epithelium within the middle ear which is locally destructive and often 
associated with infection. The patients generally present when there is 
either hearing loss or otorrhoea and the diagnosis can usually be made by 
otoscopy. 
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The photograph in figure 2-2 shows the typical otoscopic view of an attic 
cholesteatoma in a patient presenting with hearing loss and otorrhoea. 
 
 
 
Figure 2-2 Attic cholesteatoma. 
Classification of Cholesteatoma 
 
Traditionally cholesteatoma is classified into congenital and acquired. 
Congenital cholesteatoma, which is rare, occurs behind an intact tympanic 
membrane and acquired cholesteatoma which is much more common is 
generally associated with tympanic membrane defects. 
 
A useful classification might also describe the surgical extent of the disease, 
any complications and recidivistic properties.  
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A recent classification in figure 2-3 is the result of an international 
collaboration of otologists and was the subject of a consensus meeting in 
Edinburgh in 2016 (Yung et al., 2017). 
 
 
 
 
 
 
Figure 2-3 Classification of cholesteatoma from Cholesteatoma 2016 Edinburgh. 
The anatomical spaces affected by cholesteatoma are divided into T for 
tympanic cavity, A for attic and M for mastoid. S1 and S2 refer to the 
surgically awkward epitympanic space and sinus tympani which is difficult to 
access since it is medial to the facial nerve. 
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Figure 2-4 Anatomical regions for cholesteatoma classification. 
 
The cholesteatoma is staged according to the number of anatomical sites. 
Stage 1 is localized at the primary site and stage 2 refers to spread to an 
adjacent sites. Stage 3 refers to complications such as labyrinthine fistula, 
facial palsy, post auricular abscess and other extracranial complications. 
Stage 4 refers to intracranial complications such as meningitis, brain abscess 
and sinus thrombosis. 
 
Figure 2-5 shows the operative findings in 293 patients operated by the 
author. Almost all of the cases would be classified as stage 1 or 2 according 
to the classification. Ossicular erosion is common and important for hearing 
loss yet ossicular erosion and hearing loss are not part of the Edinburgh 
classification. 
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Figure 2-5 Operative findings in cholesteatoma from the author's series of patients. 
 
A case of recurring bilateral cholesteatoma in a child. 
 
Cholesteatoma in children presents a particular challenge. The disease 
spreads widely within the temporal bone and is especially troublesome if it 
occurs bilaterally as in the case described here. 
 
The case note entries are summarized over a period of 8 years between 
September 2010 and January 2018. 
 
23/09/2010: 
- DM, a boy age 7,  presented to the ENT clinic with a 2 year history of 
foul smelling discharge from the left ear. Grommets had been 
inserted at age 4 for bilateral glue ear. 
 
- Hearing was normal. Clinical examination revealed a left attic 
cholesteatoma. 
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- The mother reported that both a maternal and a fraternal uncle were 
known to have cholesteatoma. The patient and his mother have 
recently been recruited to the Genetics of Cholesteatoma project. 
 
 
 
Figure 2-6 Pedigree of DM family. Two maternal uncles are reportedly  affected. 
 
 
 
Figure 2-7 A CT scan showed opacity throughout the middle ear and mastoid with bone erosion of 
the ossicles. The right ear was normal. 
Opaque mastoid and 
eroded air cells 
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1/11/2010: 
- A left closed cavity mastoidectomy was carried out to remove a large 
cholesteatoma in the mastoid and middle ear. The roof of the 
external ear canal had been eroded by the disease and was repaired. 
The incus and the head of the malleus were removed. 
 
11/07/2011: 
- A planned revision or “2nd look” of the mastoidectomy was carried 
out to reveal and remove a small recurrent pearl of cholesteatoma 
in the attic. The stapes was seen to be clear of disease and the post- 
operative hearing gradually returned to normal by the hearing test 
of 03/09/2012. 
 
- The patient was seen annually for review and audiology. There was 
a slight decline in the hearing on the left side but the hearing on the 
right remained normal. 
 
 
28/09/2015: 
- The patient developed a discharge in the right ear and there was 
evidence of an attic pit in the drum. 
 
6/2016: 
- A CT scan showed opacity and bone erosion on the right side which 
had been completely normal on the CT scan from 5 years earlier. 
 
- There was also opacity seen on the left mastoid cavity suggestive of 
recurrent disease. 
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Figure 2-8 CT scan showing disease in both sides. 
 
 
9/2016: 
- A right closed cavity mastoidectomy was done to remove a large 
mastoid and middle ear cholesteatoma. The incus and malleus head 
were removed and there was a postoperative conductive deafness 
in what had been the better hearing ear. 
 
9/2017: 
- A left mastoidectomy revealed a massive recurrence of the 
cholesteatoma and an open cavity mastoid operation was therefore 
performed. This had recurred despite an apparently complete 
clearance of the disease in 2011, near normal hearing and a trouble 
free ear with no discharge. The photograph shows a large 
cholesteatoma being removed from the left cavity. 
 
Opaque left 
 mastoid  
cavity 
Opaque right 
mastoid cavity 
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Figure 2-9 Operative photograph showing disease in the cavity. 
1/2018: 
- The  photograph in figure 2-10 was taken of the patient having a 
revision, or planned 2nd look, mastoid operation on the right side. 
- The disease can be seen advancing around the bone of the ear canal 
and “dripping” very slowly into the cavity. The disease has eroded 
the arch of the stapes and there was a large conductive hearing loss.  
 
 
 
Figure 2-10 Cholesteatoma can be seen creeping around  from the middle ear to the mastoid cavity. 
 
 
Under surface of ear 
drum 
Cholesteatoma advancing  
into a mastoid cavity 
Bone of ear 
canal 
Cholesteatoma in the 
cavity 
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Figure 2-11 Histology of the cholesteatoma. 
 
The histology slide prepared from a sample of the cholesteatoma shows the 
typical appearance of a keratinizing squamous epithelium with and an 
underlying perimatrix which is inflamed. 
Outer epidermoid 
matrix 
 
 
Keratin sheets   
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Figure 2-12 Audiograms showing the change in the hearing over 7 years in both ears. 
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The hearing has fluctuated over a period of 7 years. At the beginning the 
patient had normal hearing.  In the most recent test the patient had good 
hearing in the low tones on the left  because there is direct contact of the 
drum with the stapes superstructure. There is a large conductive loss on the 
right as a result of loss of the stapes superstructure.  This can be repaired by 
means of an ossiculoplasty. 
 
In summary this is a child with bilateral destructive cholesteatoma and a 
family history on both sides of his mother’s family. The disease shows 
recidivism and developed in the 2nd ear “hidden in full sight” of the otologist 
who carried out regular reviews. 
 
The fact that cholesteatoma may be so destructive in children is supported 
by data from my own series (tables 2-1,2-2) which has compared the site of 
the cholesteatoma and the state of the ossicular chain in adults and children.  
In the Norfolk series there were 71 operation in 58 children and  281 
operation in 260 adults.(Jackson et al., 2018)  
 
Cholesteatoma was found to be more extensive and more likely to have 
resulted in ossicular erosion. 
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Table 2-1 Site of cholesteatoma in children and adults. 
 
 
 
 
 
Table 2-2 Ossicular erosion in children and adults. 
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Pathological theories 
 
The cells of the tympanic membrane, uniquely within the body, exhibit 
centrifugal migratory properties (Broekaert, 1990). Experiments in which 
small ink dots painted on the drum are observed by serial drum photography 
have been used to investigate the migratory pattern of the drum cells which 
originate around the umbo at the tip of the malleus and migrate radially. 
Thus the drum regenerates by migration of new cells from the centre rather 
than by superficial desquamation. Probably this is the basis of a self-cleaning 
mechanism which fails when a cholesteatoma develops. 
 
Although squamous metaplasia of middle epithelium has been proposed as 
a cause of cholesteatoma (Sadé, 1971) most otologists believe that 
cholesteatoma arises from drum epithelium either as a result of invagination 
and pocket formation or as an error of drum healing. 
 
Migration of cholesteatoma from the edge of a drum perforation is familiar 
to otologists and is surely the mechanism of causation in some cases.[Fig 
2.13] 
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Figure 2-13  Operative photographs which show a cholesteatoma apparently arising at the margin of 
a perforation. 
The magnified image shows cholesteatoma enveloping the incudo- stapedial joint. There was erosion 
of the incus long process and a 60dB  conductive hearing loss.  
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Cholesteatoma most commonly starts within a drum retraction, perhaps as 
a result of negative pressure within the middle ear. The pars flaccida, which 
lacks the strong fibrous layer of the pars tensa, is most susceptible to this 
which explains why most cholesteatoma arises in the attic region. Focal 
disruption of the basal epithelial layers of the pars flaccida in particular 
permits the ingress of keratinocytes resulting in the formation of keratinizing 
inclusion cysts (Sudhoff et al., 1996). 
 
 
 
Figure 2-14 Operative photograph showing the sack of the cholesteatoma 
 
The photograph shows how a sack of invaginated epithelium is revealed 
after some of the overlying bone has been drilled away. 
 
Essentially cholesteatoma can be regarded as a situation in which there is 
unregulated control of drum epithelium growth usually with invasion and 
hyperproliferation of the cells. Why does this occur? 
  
 
Edge of sack 
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Investigative approaches 
 
Investigators have regarded cholesteatoma as a disorder of growth control, 
not neoplasia, but rather invasion and hyperproliferation of keratinizing 
squamous epithelium. 
 
Studies  have compared the molecular chemistry of cholesteatoma cells with 
post auricular skin taken at the time of operation. Immunohistochemistry 
and microarray analysis has been used in many reports of this type to try 
and understand the apparently disordered growth regulation (Olszewska et 
al., 2004, Kwon et al., 2006) (Macias et al., 2013b, Friedland et al., 2009, Kuo, 
2015). These sort of studies investigate gene expression in tissue after the 
biological change in the cells associated with the cholesteatoma has 
developed and no distinction can be made between somatic mutations 
which are not inherited and germ line mutations which are the fundamental 
cause of a genetic trait. 
  
A variety of cytokines and other molecular mechanisms have been studied 
by this technique: 
 
- Cytokaratins 13/16 and proliferating cell nuclear antigen: (Jin et al., 
2011) 
- Transforming Growth Factor Alpha: (Ergün et al., 1996) 
- c-Jun and P53: (Shinoda and Huang, 1995) 
- c-Myc: (Holly et al., 1995)  
       -     Gap junction protein expression: (Klenke et al., 2012a) 
 
Animal models of cholesteatoma have also been described (Yamamoto-
Fukuda et al., 2011). Ligation of the ear canal in Mongolian gerbils can be 
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used to experimentally create cholesteatoma (McGinn et al., 1982). 
Mutated mice models deficient in Transforming Growth Factors [TGF] (Ergün 
et al.) have been studied (Wright et al., 1996). 
 
Such approaches have suggested a number of relevant molecular pathways 
in which hyperproliferation of keratinocytes associated with inflammatory 
reactions are triggered by complex immune and cytokine messenger 
systems (Macias et al., 2013b). 
Cytokines 
 
These are small protein signalling molecules involved with cell to cell 
communication  particularly in immune responses. The growth of 
cholesteatoma is associated with an immune infiltration and the release of 
cytokines and growth factors. Keratinocyte proliferation is associated with 
expression of transforming growth factor alpha [TGF], epidermal growth 
factor [EGF] and its receptor EGFR (Bujía et al., 1996). DNA microarray chip 
analysis studies such as that of Macias et al comparing the cholesteatoma 
cells to the postauricular skin have shown that genes involved in cytokine 
mediated inflammation have altered expression (Macias et al., 2013b). 
Cytokeratins  
 
Cytokeratins or keratins [K] are filamentous proteins [number 1 to 20] 
present in epithelial cells. K expression varies with stages of differentiation 
and as such K expression has been used to better understand cell dynamics. 
The K expression demonstrated by such studies reflects the 
hyperkeratinisation of the developing cholesteatoma but does not explain 
why this occurs (Kim et al., 2001, Olszewska and Sudhoff, 2007). 
 
A cycle of keratinocyte activation in wound healing and other conditions has 
been postulated which is controlled by the activation of growth factors and 
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cytokines. Resting keratinocytes either differentiate or activate in response 
to chemical signals which affect the production of various keratin K proteins 
within the cell. A disruption of such a cell cycle might have importance in 
cholesteatoma pathology and certainly an accumulation of excessive keratin 
and migration of keratinocytes are hallmarks of the disease. 
 
In the cycle presented in the diagram 2-15 basal keratinocytes producing K5 
and K14, either differentiate to produce K1 and K10 or receive a signal from 
IL-1 and become activated to express K6 and K16. TNF- and TGF- keep the 
keratinocyte activated until a contracting signal from IFN- induces K17 and 
causes keratinocyte contraction. TGF- is a signal for the cell to revert to the 
resting state (Freedberg et al., 2001). 
 
 
 
  
Figure 2-15 Drawing of a keratinocyte cycle 
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The role of infection 
 
Many cholesteatomas are associated with bacterial infection and otorrhoea. 
Might bacterial infection induce immune mechanisms important in 
cholesteatoma proliferation? The anaerobic bacteria Pseudomonas 
aeruginosa creates a biofilm lipopolysaccharide that has been shown to 
induce keratinocyte hyperproliferation (Preciado, 2012). The destructive 
nature of the proliferating keratinocytes is increased in the presence of 
infection. However many cholesteatomas develop insidiously in the 
apparent absence of active bacterial infection and infection is probably  not 
the cause of cholesteatoma per se. 
 
Conclusion 
 
Cholesteatoma has defied explanation since it was first described. Surgical 
pathology and histopathological examination have suggested a number of 
pathogenic processes and molecular studies using immunohistochemistry 
and microarray analysis in particular to compare cholesteatoma with 
matched post auricular skin have unravelled some of aspects of protein 
signalling and expression at a cellular level. 
 
The Genetics of Cholesteatoma whole exome sequencing pilot study 
described in this thesis has adopted a completely different approach. It 
makes use of the observations about a familial tendency and seeks to 
identify mutations that co segregate with the phenotype. Work which has 
identified biochemical pathways of interest informs this genome study of 
the molecular factors and biological pathways that have a role in 
cholesteatoma formation.  
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Chapter 3 The Epidemiology of Cholesteatoma 
 
A literature review and a presentation of ear surgery data from Norfolk and 
England. 
 
Abstract for chapter 3 
Background 
 
Epidemiological information about cholesteatoma might inform theories of 
genetic causation that are the subject of this specific investigation. Basic 
data about age of onset and gender can be extracted from published case 
series and national health statistical databases. There is much less 
information about other commonly reported epidemiological characteristics 
such as social class and comorbidity, for example the association with 
childhood ear infection. 
 
Objectives 
 
1 To complete a systematic literature review of epidemiology studies about 
cholesteatoma.  
 
2 To contribute data about the age and sex and anatomical distribution of 
the disease in defined UK populations within Norfolk and England. 
 
Data sources 
 
1. Online databases: Medline, EMBASE, CINAHL. 
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2. Contact Centre Team NHS Digital that collates Hospital Episode Statistics 
for England.  
 
3. The International Otology Database: www.ear-audit.net . 
 
Search criteria terms 
 
Cholesteatoma, middle ear and epidemiology.  
 
Study eligibility for literature review 
 
The search criteria terms cholesteatoma, middle ear, epidemiology were 
used. 
No restrictions on date. 
English language papers. 
 
Appraisal and synthesis of literature review 
 
A total of 154 references were revealed by the search strategy. Abstracts 
were hand scrutinized for content of interest. Studies were sorted into 
observational population studies and studies reporting institutional or 
personal case series with epidemiological observations. 
Studies reporting comorbidity associations and syndromal associations and 
also other factors such as social deprivation were all assessed for relevance. 
 
Results 
 
Summary findings from 21 articles about the epidemiology of cholesteatoma 
are tabulated. Epidemiological observations and associations are described. 
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Conclusions 
 
Epidemiological aspects of cholesteatoma have attracted rather little 
interest in the literature. What is known about the epidemiology is derived 
largely from a number of case series and from identifiable disease in cases 
with syndromal associations. It is known that the condition is slightly more 
frequent in males and that there is a peak age of incidence in the second 
decade of life. Association with childhood ear infection is well described but 
by no means universal.  
 
Causation remains enigmatic but epidemiology can inform futures avenues 
of research including research into the genetic basis of the disease that is 
the subject of this thesis. 
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Introduction 
Rationale 
 
Cholesteatoma is an enigmatic condition of the middle ear of unknown 
causation. Observations reported by the author of a familial tendency in East 
Anglia suggest a role for genetic factors (Prinsley, 2009a). Epidemiological 
observations have the potential to inform studies into the possible genetic 
basis of this condition. A systematic epidemiological  literature review has 
been undertaken and observations collated from a personal database of 
cases and from NHS Digital that collates cases nationally are also presented. 
Objectives 
 
1. To complete a systematic literature review of epidemiology studies 
about cholesteatoma.  
 
2. To contribute data about the age and sex and anatomical distribution of 
the disease in defined UK populations within Norfolk and England. 
 
Background 
 
Cholesteatoma, although not exceptionally rare, can hardly be considered 
an epidemic in the usually understood meaning of the word. The Oxford 
English Dictionary describes an epidemic as a disease prevalent in a 
community at a particular time and produced by special causes not generally 
present in the affected locality. It is this concept of special cause that is being 
sought by a review of disease association presented in this chapter. 
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Methods 
Information sources 
 
Medline, EMBASE, CINAHL. No restrictions on date or language. 
 
Search history 
 
The search criteria terms cholesteatoma, middle ear, epidemiology were 
used as follows: 
1. Medline; *CHOLESTEATOMA/ OR *CHOLESTEATOMA, MIDDLE EAR/; 4100 
results. 
2. Medline; *EPIDEMIOLOGY/; 657533 results. 
3. Medline; 1 AND 2; 70 results. 
4. EMBASE; *CHOLESTEATOMA/; 4165 results. 
5. EMBASE; *EPIDEMIOLOGY/; 42852 results. 
6. EMBASE; 4 AND 5; 1 results. 
7. EMBASE; exp CHOLESTEATOMA/ep [ep=Epidemiology]; 95 results. 
8. CINAHL; *CHOLESTEATOMA/; 427 results. 
9. CINAHL; exp EPIDEMIOLOGY/; 318880 results. 
10. CINAHL; 8 AND 9; 20 results. 
 
Eligibility for inclusion in the literature review 
 
Abstracts of 154 different articles identified using the search strategy above 
were scrutinized; full text was obtained for clarity where necessary. 
Inclusion criteria 
 
Articles describing populations or case series containing clear 
epidemiological data were identified.  
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Exclusion criteria 
 Small retrospective series of operated cases and operative technique. 
 Anatomical reports about disease distribution and the facial nerve. 
 Radiological reports about disease extent. 
 Articles about pathological theories of causation. 
 Bacteriology articles. 
 “Epidemiological” reports with no information about denominator 
populations. 
 General cholesteatoma reviews with no original observations. 
 
 
Data collection and synthesis of results 
 
Epidemiological data such as incidence, age, gender, syndrome and disease 
association have been tabulated for 21 articles together with a note of the 
main observation made in the report. 
 
 
Figure 3-1 Filtering of the epidemiology  literature review. 
21
tabulated
134 
exclusions
154 abstracts
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Risk of bias 
 
Retrospective population based cohort studies that use routinely collected 
hospital data and statistics are of great value because almost all cases of 
cholesteatoma that require surgery require admission to hospital. Personal 
and institutional reports that comprise much of the literature are subject to 
reporting bias and are hard to verify. 
 
 
Results 
Study selection 
 
The electronic library search revealed 154 references. Abstracts were 
screened and assessed for eligibility. The summary data for 21 articles of 
particular interest are tabulated. 
Study characteristics identified 
 
The author and country of origin together with date of the study/publication 
were identified. The study population was described. Some institutional 
reports describe cholesteatoma case series with little definite information 
about denominator populations of unaffected patients.  Other cohort 
reports look at cholesteatoma in the context of whole populations. 
Incidence and gender are tabulated where this information is available. 
Some reports identify a social class effect. The summary observations in 
each of the reports are tabulated. 
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Table of results 
 
1st Author  
Country 
Dates  Study 
population 
Incidence  
Gender 
Social 
Class 
Main 
observations 
Bergamaschi 
Italy 
(Bergamaschi et 
al., 2008a) 
 173 people 
with Turner 
Syndrome 
94 had 
middle ear 
disease 15% 
had chole 
 1st and 2nd 
arch growth 
disturbance 
associated 
with ear 
disease 
Djurhuus 
Denmark 
(Djurhuus et al., 
2010) 
1977 
to 
2007 
13,606 
STMEC  
Approx. 5 
million pop 
14.3/9.1/m/
f/100,000 
in 1982 
8.5/5.4/m/f/
100,000 
in 2007 
No 
affect 
Decrease in 
incidence of 
surgery for 
chole in 30 y 
period 
Djurhuus 
Denmark 
(Djurhuus et al., 
2015a) 
1997 
to 
2011 
In 217,206 
children 
who had 
VTI  
374 had 
STMEC  
 
36,981 
children 
had no VTI 
5 had 
STMEC 
1.71% of VTI 
patients 
 
 
 
 
 
0.013% of 
non VTI 
patients 
 Prolonged 
otitis media 
requiring VTI 
makes chole 
much more 
likely. 
Increasing 
number of 
VTI in an 
individual 
increases risk 
for chole 
Djurhuus 
Denmark 
(Djurhuus et al., 
2015c) 
1936 
to 
2009 
 
 8,593 cleft 
patients 
and 6989 
non 
syndromic 
siblings 
249,708 
controls 
and 175,724 
siblings of 
controls  
201 and 21 
STMEC 
485 and 332 
STMEC 
 
5% sample 
of Danish 
population 
249,708 
people 485 
chole 0.2%, 
175,724 
siblings 322 
chole 0.2% 
 HR CLAP  14, 
HR CL 20 
HR  siblings 
of CP 2.1 
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Fiedler(Fiedler 
et al., 2013) 
Germany 
2005 All ENT 
depts in 1 
German 
state  
1037 pts 
Ear surgery 
numbers for 
various 
disorders 
 15/100,000 
pop 
STMEC 
Harris 
Canada(Harris et 
al., 2013) 
1981 
to 
2005 
Toronto 
Sick 
Children 
Hospital 
2737 
palatoplasty 
children 
developed 
44 chole age 
5 to 18 
which is 
2.2%.  200 x 
the base 
rate 
CLAP 3 x risk 
of CP alone 
 
 Strong CLAP 
association 
Hasegawa 
Japan(Hasegawa 
et al., 2006) 
 171 chole 
Tohoku 
University 
Hospital 
m/f = 
171/100 
 
 
 Sniffing habit 
related to 
hearing and 
air bone gap 
in chole 
patients 
Kemppainn 
Finland(Kemppa
inen et al., 1999) 
1982 
to 
1991 
500 chole 
patients in 2 
hospitals in 
Finland 
Incidence of 
9.2/100,000 
Previous VTI 
in 10.2% 
8% of CLAP 
patients 
No 
class 
effect 
Typical 
personal/insti
tution report 
over 10 y 
Khaiid Raja 
UK(Khalid-Raja 
et al., 2015) 
4 y of 
NHS 
data 
UK Health 
statistic for 
4 separate 
years 
See Fig 3-7 Yes Chole 
operations 
more 
common in 
areas of 
higher 
multiple 
deprivation 
Kinsella 
Ireland(Kinsella, 
1996) 
1965 
to 
1988 
Clinical 
notes of 
patients 
having ear 
surgery in 2 
hospitals 
Chole varied 
from 0.01 to 
0.16/1000 
population 
No change 
first 5 y to 
last 5 y 
despite 8 x 
increase in 
VTI 
 No reduction 
chole by VTI 
Mason(Mason 
and Wabnitz, 
2002) 
Australia 
1998 
to 
2001 
Case review 
at Royal 
Darwin 
Hospital 
5/100,000 
aboriginal 
and 
6/100,000 
 No increase 
in chole in 
aboriginal 
patients 
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non 
aboriginal 
despite 
greater 
incidence of 
CSOM 
Maw(Maw et 
al., 2011) 
England 
2001 Avon 
Study of 
Parents and 
Children 
Video 
otoscopy of 
6908 
children 
 15 /6908 had 
overt or 
suspected 
chole 
Migirov 
Russia(Migirov, 
2012) 
2009 
to 
2012 
237 right 
handed 
patients 
31 left 
handed 
 
m/f = 
158/79 
6 to 81 y 
 
 59.5% right 
handed 
patients had 
right chole 
83.9% left 
handed 
patients had 
left  
chole 
Padgham 
Scotland 
(Padgham et al., 
1989) 
1966 
to 
1986 
Tayside  Chole 
incidence 
0.94/10,000 
to 
1.88/10,000 
Mean 
1.32/10,000 
VTI 
increased 60 
x 
 No reduction  
chole  by VTI 
Prescott 
S 
Africa(Prescott, 
1999) 
1988 
to 
1996 
96 chole in 
81 children 
in S African 
hospital 
m/f = 44/37 
age 2 to 12 
24/96 
presented 
with 
mastoiditis 
 
 Late 
presentation 
Extensive 
disease 
and poor FU 
typical in 
“developing” 
country 
Rakover 
Israel(Rakover 
et al., 2000) 
1961 
to 
1998 
Israeli 
hospital 
413 chole op 
1961 to 
1970 
228 chole op 
1989 to 
1998 
30y gap in 
which VTI 
was 
introduced 
20 to 6.6 
/10,000 
population 
 Belief that 
VTI reduces 
long term 
chole 
incidence 
Roland 
England(Roland 
et al., 1992) 
1963 
to 
1990 
Paediatric 
population 
in Liverpool 
Decline in 
mastoid 
operations 
and 
 Increasing 
VTI not 
correlated 
with reduced 
  
 
 
64 
increased 
use of VTI  
But no 
correlation 
mastoid 
surgery 
Shibata 
Japan(Shibata et 
al., 2015) 
 Fukuoka 
City, Japan 
 
Incidence 
6.8 to 
10/100,000  
 
 PMH of otitis 
media 
and habitual 
sniffing 
relevant 
Spilsbury 
Australia 
(Spilsbury et al., 
2010) 
1980 
to 
2004 
45,980 
children 
who had 
VTI in W 
Australia 
460 
developed 
chole 
Increasing 
number of 
VTI 
increased 
chance of 
chole  
1 VTI 0.9%,2 
VTI 
2.1%,3VTI 
3.8%,4VTI 
5.2% 
Rural 
effect 
Approx 1% of 
children who 
have had a 
VTI get chole 
Wang(Wang et 
al., 2015) 
Taiwan 
1997 
to 
2008 
37,124 
cohort 
osteoporosis 
See Fig 3-8  1.31 HR for 
chole in 
osteoporosis 
Zakzouk(Van 
Rompaey et al.) 
Saudi Arabia 
2000 Epidem 
study in 
Central 
Province 
9/9540 
children had 
chole in 
1982 
6/6421 
children had 
chole in 
1991 
 
 Part of a 
study 
showing 
decrease in 
CSOM but no 
change in 
chole 
 
Table 3-1 Summary of literature table 
 
STMEC     Surgically treated middle ear cholesteatoma 
Chole       Cholesteatoma 
CSOM      Chronic suppurative otitis media 
VTI            Ventilation tube insertion  
HR            Hazard ratio 
CLAP        Cleft lip and palate 
CP/CL       Cleft palate/lip 
FU            Follow up 
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Epidemiological Statistics for England and for Norfolk 
 
The NHS Hospital Episode Statistic for England [Fig 3.2] shows that there 
were 5,201 operations for patients who were coded as having a diagnosis of 
cholesteatoma of the middle ear [H71.X] in the year 2014/15. This gives an 
indication of the annual incidence of surgical approaches to cholesteatoma 
in England. The peak age group is 10 to 14 years and there was an almost 3 
to 2 male to female ratio. If the population of England is approximately 
50,000,000 then this is approximately 10 cholesteatoma operations per 
100,000 population per year.  
 
Cholesteatoma of the middle ear 2014/15: Health and Social Care 
Information Centre English NHS. This chart was devised by the author using 
data from NHS Digital. 
 
 
 
 
Figure 3-2 Cholesteatoma of the middle ear 2014/2015 English NHS 
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Figure 3-3 shows that there are 406 operations for cholesteatoma in the 
series of patients recorded by the author over 10 years.  The peak age group 
is also 10 to 14 years. There is another peak in the age group 40 to 49 but 
broadly the distribution of age is similar to the national picture. The sex 
distribution is somewhat more equal in the Norfolk cases; 52.7% male in 
Norfolk v 59.4% male nationally. 
 
This is approximately 40 cases each year suggesting a population of about 
400,000 people, which is approximately 10 operations per 100,000 
population per year. The two Norfolk  hospitals serve a population of about 
750,000 people but there are several other otological surgeons. 
 
 
Figure 3-3 Cholesteatoma surgery data from www.ear-audit .net for the author’s cases 2006 – 2016. 
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Discussion 
Incidence 
 
Djurhuus (Djurhuus et al., 2010) has published an analysis of Danish national 
health statistics that has studied 13,606 cases of cholesteatoma [Figure 3.4]. 
The incidence of cholesteatoma was a maximum of 14.3/100,000 in males 
in 1982 falling to 8.5/100,000 in 2007. There was a similar fall in female 
cases.  Age specific incidence per 100,000 person ears is also presented. The 
figures are taken from the Djurhuus’ study. 
 
 
 
Figure 3-4 The  incidence rate of cholesteatoma in Denmark. 
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Figure 3-5 Cholesteatoma in Denmark. Age at surgery. 
 
 
The reported incidence per 100,000 in Scotland of 13.2, Finland of 9.2 and 
Japan of 6.8 to 10 look broadly similar to the Danish figures. In Germany the 
incidence of STMEC was 15 per 100,000 in one federal state in 2005 (Fiedler 
et al., 2013) and the figures presented from Norfolk and from NHS Digital 
also support this. Maw identified 15/6908 children screened by video-
otoscopy as having overt or suspected cholesteatoma that seems a 
remarkably high number and may reflect a subjective opinion of suspected 
cholesteatoma on video images (Maw et al., 2011). 
 
Gender 
 
All reports of gender data suggest that the condition is more common in 
males and this is also the direct observation from the national and local 
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databases. The English statistic for 2014/15 was 59.4% male and the Norfolk 
statistic for 2006 to 2016 was 52.7% male. 
 
There is an association with Turner syndrome, which is a condition in which 
there is no Y chromosome. Reports emphasize the anatomical changes in 
the skull base associated with Turner syndrome as a possible explanation 
but a fascinating possibility is that there might also be an X linked disease 
association to explain the male to female ratio? The author has several 
patients with Turner syndrome and chronic middle ear disease. 
 
Age of onset 
 
The databases show that the peak age for surgical intervention is in early 
teenage years but that there is a wide distribution with some patients 
operated in the 7th and 8th decade of life. The age distribution in Denmark 
from Djurhuus  shown in figure 3-5 closely matches the pattern of the 
Norfolk patients with a bulge in later middle age. 
 
 
Childhood otitis media with effusion [OME] and ventilation tube insertion [VTI] 
 
Spilsbury (Spilsbury et al., 2010) reports a huge study from W Australia of 
45,980 children who had a VTI between 1980 and 2004 [figure 3-6]. 460 
patients went on to develop cholesteatoma, which is almost exactly 1%. 
Repeated tube insertions increased the likelihood of cholesteatoma 
although early intervention seemed to reduce it. Adenoidectomy was 
associated with a 27% reduction in the chance of developing cholesteatoma. 
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Spilsbury et al. show that the chance of developing a cholesteatoma 
increases with increasing numbers of VTI operations [with permission] 
 
 
 
Figure 3-6 Spilsbury et al Western Australia showing that the chance of a cholesteatoma increases 
with additional VTI operations. 
Djurhuus (Djurhuus et al., 2010) studied 217,206 children from the Danish 
National Patient Register born between 1996 and 2011 who had a VTI and 
found that 374 of these children went on to have STMEC which is 1.7% of 
the patients.  Later age of first VTI and greater intervals between successive 
VTI operations increased the chance of STMEC. A matched group of 36,981 
children from the Danish National Patient Register without VTI was 
scrutinized and only five of these people had STMEC [0.013% of the non-VTI 
sample]. 
 
It is therefore clear that there is an association between childhood OME, VTI 
and cholesteatoma. The question of whether the widespread introduction 
of VTI for childhood glue ear affected the amount of cholesteatoma surgery 
has been studied in two similar papers from Scotland and Northern Ireland 
reporting that the great increase in the use of VTI between the 1960s and 
the 1980s was associated with no change in the amount of STMEC. Rackover 
however makes an opposite interpretation of data from Israel in a study that 
identified 413 operations in the 1961 to 1970 and 228 operations between 
1989 and 1998 which represented a fall for 20 per 10,000 population per 
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decade to 6.6 per 10,000 population. The demographic makeup of the State 
of Israel changed markedly as a result of mass immigration in the intervening 
30 years and this may be relevant. 
 
Social class 
 
A social deprivation effect is explored in the paper by Khalid Raja. The Index 
of Multiple Deprivation [IMD] deciles in figure 3-7  show that the numbers 
of operations for cholesteatoma was greater in areas of the country with a 
higher IMD(Khalid-Raja et al., 2015). IMD ranks 7 domains including income 
deprivation, employment deprivation and health deprivation and disability. 
This paper used data from the UK office for national statistics and calculated 
the number of cholesteatoma operations in each UK local government 
authority for 4 separate years. The paper from Finland  however found no 
social class effect but there are few details about how social class was 
estimated in this paper. 
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 A chart showing the number of operations in a health district in relation to 
the deciles of index of multiple deprivation [from Khalid Raja et al with 
permission] 
 
 
Figure 3-7 Effect of social class. Each decile represents an index of social deprivation.  
 
 
Cleft lip and palate and other syndromes 
 
There is a much-increased incidence of glue ear in children with CLAP or CP 
alone. A large study from Toronto over 25 years showed that there was a 
200-fold increase in the cholesteatoma rate over baseline in palatoplasty 
patients [2.2% of 2737 patients]. A Danish whole population study showed 
a similar rate of 2.34% cholesteatomas in palatoplasty patients. Intriguingly 
non-CLAP siblings of such patients were found to have a more than doubled 
risk of cholesteatoma which suggests a genetic factor. 
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An Italian study of hearing problems in Turner syndrome showed that 15% 
of 173 patients with Turner syndrome had a cholesteatoma (Bergamaschi et 
al., 2008a). Turner syndrome, which is caused by the deletion of one of the 
X chromosomes, is one of the commonest major chromosomal disorders 
occurring in 50 per 100,000 live female births. Turner syndrome is associated 
with short stature and various dysmorphic features. The association with 
chronic otitis media was reported in 1963 in Sweden. The Italian report 
refers to literature suggesting that anatomical features of Turner Syndrome 
may predispose to middle ear disease and middle ear ventilation difficulties, 
although it is unclear if there is as discrete increase in the risk of a 
cholesteatoma. 
 
Other factors of interest 
 
A curious association of cholesteatoma with habitual sniffing is described in 
two papers from Japan (Shibata et al., 2015, Hasegawa et al., 2006). The 
premise is that habitual sucking causes movement of a floppy segment of 
ear drum leading to chronic retraction and a predisposition to 
cholesteatoma. Another enigmatic association was the association of 
handedness with laterality of unilateral cholesteatoma described in a paper 
by Migirov. Right ears were more often affected in right-handed people and 
left ears in left handed people.  
 
Osteoporosis 
 
A study from Taiwan  using the National Health Statistic service showed that 
there was a small increase in the incidence of cholesteatoma in patients with 
a diagnosis of osteoporosis. Some speculation as to the mechanism of bone 
loss in osteoporosis is included in this paper together with a bizarre 
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suggestion that otolaryngologists evaluate the middle ear in patients with 
osteoporosis. 
 
Chart showing the cumulative incidence of cholesteatoma in patients with 
and without osteoporosis (Wang et al., 2015). 
 
 
 
Figure 3-8 Effect of osteoporosis. 
 
Ethnicity 
 
Little useful data about this has been identified. In the Northern Territory of 
Australia chronic ear infection is common in the aboriginal population. The 
hospital records from the Royal Darwin Hospital showed that there was 
however no greater incidence of cholesteatoma in the aboriginal people as 
compared to the non-indigenous Australians (Mason and Wabnitz, 2002). In 
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Saudi Arabia a survey of children showed a cholesteatoma incidence in 
children of about 1 in 1000 and is thus much higher than in other population 
groups reported above (Zakzouk and Hajjaj, 2002). 
 
A 2004 WHO report about Chronic Suppurative Otitis Media presents data 
about the incidence of CSOM and although no clear distinction about the 
diagnosis of cholesteatoma is usefully made in this report the disease does 
occur worldwide. 
Conclusion 
 
Cholesteatoma is an enigmatic condition of unknown aetiology. 
Epidemiological approaches can identify associations but since this 
condition is rare conventional epidemiological investigations of 
pathogenesis or causation are problematic.  Cholesteatoma is seen to affect 
all age groups with a main peak in teenagers and a small  male 
predominance. Sometimes cholesteatoma presents for the first time in old 
age. The Norfolk patients have a somewhat different sex and age 
distribution from the UK average in the year 2014/15. Many others around 
the world have reported series of patients with cholesteatoma and shown 
that it causes serious morbidity and mortality.  
 
The literature suggests an association with CSOM and with a history of 
ventilation tube insertion although association and causation are quite 
different. There are reports of syndrome associations most notably with 
cleft palate. Some have suggested an association with social class and 
economic disadvantage but this may simply reflect the greater incidence of 
CSOM in such populations. 
 
Genetic approaches to  the aetiology of cholesteatoma are the subject of 
this thesis and the literature about this is reviewed in a separate chapter.  
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Chapter 4 The Genetics of Cholesteatoma Literature 
Review 
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Abstract of chapter 4 
 
Objective 
 
A cholesteatoma is a mass of keratinizing epithelium in the middle ear. It is 
a rare disorder that is associated with significant morbidity, and its causative 
risk factors are poorly understood; on a global scale up to a million people 
are affected by this each year.  A systematic literature review to identify 
reports about the heritability of cholesteatoma or any constitutional genetic 
factors that may be associated with its aetiology has been conducted. 
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Data sources 
 
A systematic search of MEDLINE [EBSCO] and 2 databases of curated genetic 
research [OMIM and Phenopedia] was conducted.   
Study selection 
 
The participants and populations of interest for this review were people 
treated for cholesteatoma and their family members. The studies of interest 
reported evidence of heritability for the trait, or any association with 
congenital syndromes and particular genetic variants. 
 
Data extraction 
 
The searches identified 449 unique studies, of which 35 were included in the 
final narrative synthesis. 
 
Data synthesis 
 
A narrative synthesis was conducted and data were tabulated to record 
characteristics, including study design, genetic data and author conclusions. 
In a few case-reports, congenital and acquired cholesteatoma have been 
shown to segregate within families in the pattern typical of a monogenic or 
oligogenic disorder with incomplete penetrance.  Evidence from syndromic 
cases suggest that genes controlling ear morphology may be risk factors for 
cholesteatoma formation.   
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Conclusion 
 
This systematic review about the genetics of cholesteatoma identified a 
small body of relevant literature that provides evidence of a heritable 
component for its aetiology. Cholesteatoma is a complex and 
heterogeneous clinical phenotype, often associated with chronic otitis 
media and with some rare congenital syndromes known to affect ear 
morphology and related pathologies. 
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Introduction 
 
A cholesteatoma is a self-perpetuating erosive mass of stratified keratinising 
squamous epithelium in the middle ear (Bhutta et al., 2011). Cholesteatoma 
has both an acquired and a congenital form. It activates osteoclasts and so 
will erode through bone, which may include the endocranium, with an 
attendant risk of life-threatening intracranial infection. 
 
The acquired form of cholesteatoma originates as an inward growth from 
the lateral epithelium of the tympanic membrane. A typical sequence of 
events in the onset of the disease includes a history of chronic otitis media 
[COM] in childhood, subsequent development of retraction of the tympanic 
membrane, and then a cholesteatoma developing within and perforating 
through this retraction.  This seems to particularly occur if the retraction is 
located in the superior tympanic membrane [pars flaccida] (Caye-Thomasen 
et al., 2008, Schilder et al., 1995, Maw and Bawden, 1994).  In children with 
a history of chronic otitis media with effusion [COME], 15-35% will develop 
a retraction of the pars flaccida [at up to 25 years follow up], but only 0.1-
2% will develop a cholesteatoma [at up to 8 years follow up] (Schilder et al., 
1995, Tos and Poulsen, 1976, Bonding and Lorenzen, 1974, MacKinnon, 
1971).   Both presence and duration of COME are predictive of tympanic 
membrane retraction (Maw and Bawden, 1994, Schilder et al., 1995), but 
tympanic retraction has been documented to occur in the absence of 
preceding COME (Schilder et al., 1995).  However histological studies suggest 
that in such cases there is nevertheless chronic middle ear inflammation, it 
is just not clinically apparent (Yoon et al., 1990). Thus cholesteatoma is 
predisposed to by COM, but only a small proportion of those with COM will 
develop cholesteatoma.  What determines the transition from COM to 
cholesteatoma is not known, but could be due to environmental factors, 
heritable factors, or random effects.  But those who develop cholesteatoma 
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have been reported to have between a 7% and a 20 % chance of developing 
disease in the contralateral ear (Rosenfeld et al., 1992a, Rosenfeld et al., 
1992b, Aquino et al., 2011), highlighting the importance of shared genes and 
shared environments. 
 
Cholesteatoma can also be found behind an intact tympanic membrane 
(Kazahaya and Potsic, 2004).  This form is thought to be congenital, and may 
result from persistence of the foetal epidermoid formation, a small 
collection of squamous epithelial cells in the middle ear that normally 
undergoes apoptosis before or shortly after birth. Congenital cholesteatoma 
can grow laterally and erode through the tympanic membrane, and at that 
point it can be difficult to differentiate congenital from acquired disease.    
 
Cholesteatoma is a rare disorder [1:10,000 per year] (Bhutta et al., 2011), 
and therefore epidemiological studies are difficult to conduct, and causative 
risk factors are still poorly understood.  The citations about cholesteatoma 
in the definitive catalogue of genes and genetic diseases, Online Mendelian 
Inheritance in Man, documents minimal evidence for the Mendelian 
inheritance of this disorder (Graham and Allanson, 1999).  However, reports 
of familial clustering of disease and of association with genetic syndromes 
[reviewed here] suggest underlying, but as yet unidentified genetic risk 
factors.  Identifying these could enhance our understanding of 
disease biology, and open up pathways for diagnostic screening, and 
therapeutic interventions. 
 
One way to identify candidate genetic factors is through analysis of products 
of gene expression in pathological specimens.  There are two published 
large-scale analyses comparing RNA transcript expression in cholesteatoma 
to that in skin of the external auditory canal skin.  These have shown several 
hundred genes are differentially regulated in cholesteatoma samples, 
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including genes with products involved in growth, differentiation, signal 
transduction, cell communication, protein metabolism, and cytoskeleton 
formation (Klenke et al., 2012a, Macias et al., 2013a).  However, the results 
from these studies are inconsistent, and are measuring gene expression 
once cholesteatoma has formed, and so have failed to significantly further 
our understanding of constitutional risk. 
 
Here described are the  findings from a systematic review of the genetics of 
congenital and acquired cholesteatoma.  The aims from this review were to 
describe how susceptibility is transmitted within families showing disease 
clustering, to better understand the genetic architecture of disease, and to 
document any genotypes shown to co-segregate with the cholesteatoma 
phenotype. It was also the aim of the review  to classify genetic syndromes 
associated with increased risk of cholesteatoma, which may implicate 
candidate genetic loci for further investigation.  
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Materials and methods 
 
Objectives 
 
To synthesize published evidence that addresses the following questions: 
 
(1) Can the development of a cholesteatoma be described as a heritable 
trait, or is there a genetic predisposition to cholesteatoma within some 
families? 
 
(2) Have any genetic alterations or congenital syndromes been associated 
with cholesteatoma? 
 
Registration of the method 
 
The protocol was registered with the Prospero international prospective 
register of systematic reviews database in June 2015 (Jennings, 2015). 
 
Search strategy 
 
The MEDLINE [EBSCO], OMIM (http://www.ncbi.nlm.nih.gov/omim), and 
Public Health genomics Knowledge Base were interrogated 
 (https://phgkb.cdc.gov/HuGENavigator/startPagePhenoPedia.do) 
 from 1980 to July 2015 using the terms “Cholesteatoma” AND “famil* [OR 
Gene* OR hered* OR inherit* OR syndrom* OR kindred OR pedigree OR 
oncogene* OR tumour suppressor OR tumor suppressor OR epigenetic* OR 
mutat* OR somatic OR homeobox]”.  We supplemented the search with 
relevant references identified in the citation lists at the article review stage.   
  
 
 
83 
 
 
Inclusion and exclusion criteria 
 
Studies were identified from the titles and abstracts  using the following 
inclusion criteria:  
Primary studies of kindreds that provide information about familial 
clustering. 
Primary epidemiological studies that provide evidence of heritability 
including ethnic differences. 
Relevant systematic reviews that provide information about genetics or 
heredity for cholesteatoma. 
Case Reports that refer to familial clustering of the cholesteatoma 
phenotype [> 1 family member affected]. 
Case Reports or epidemiological studies that provide evidence of association 
between cholesteatoma and syndromes. 
Studies were excluded if they were general narrative reviews or opinion 
pieces; about non-human or experimental disease models; or described 
pathologies other than cholesteatoma. 
 
Study selection and data extraction 
 
Full reports of potentially relevant articles were retrieved and data were 
extracted. The study design, patient characteristics, and nature of the 
outcomes were collated and coded red for exclusion; green for inclusion; 
and amber to indicate uncertainty [‘RAG review’]. When there were 
uncertainties about inclusion or data interpretation, the articles were 
discussed by the reviewers to reach consensus. All studies that met the 
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inclusion criteria were included regardless of quality, which was 
subsequently appraised.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
 
 
Data synthesis 
 
A narrative synthesis was conducted to explore the review questions about 
heritability and genetic associations reported for the cholesteatoma 
phenotype. The date of the study, first author, study design, number of 
subjects, sub-type of cholesteatoma, genetic investigations [including family 
history], associated congenital syndromes, gene nomenclature, and direct 
quotations from discussion or conclusions were tabulated. 
 
 Risk bias and quality assessment 
 
Appraisal of the quality of epidemiological studies by reference to the 
Strengthening Reporting of Observational Studies STROBE guidelines and 
the Strengthening Reporting of Genetic Association Studies (STREGA) 
guidelines (Little et al., 2009) was performed. The evidence for each study  
was mapped to the five levels  described by the Oxford Centre for Evidence 
Based Medicine (Oxford Centre for Evidence-based Medicine – Levels of 
Evidence (March 2009)). 
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Figure 4-1 Flow chart showing selection of articles for review The identification and screening of 
studies for inclusion in the narrative synthesis is illustrated in this PRISMA flow diagram. 
OMIM: Online Mendelian Inheritance in Man (NCBI) 
Phenopedia is an information database curated by the US Center for Disease Control 
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Results 
Study selection and data extraction 
 
The search identified 449 unique studies, of which 36 met the initial 
inclusion criteria. Most studies were excluded at the abstract or primary 
manuscript review stage; but six manuscripts were excluded at the data 
extraction stage because there were no relevant primary data identified 
about cholesteatoma or genetic phenomena (Serra et al., 2003, Blaser et al., 
2006, Plester, 1980, Tange et al., 2000), or because the paper described 
external auditory canal cholesteatoma (Gadre and Gadre, 1989). The studies 
identified in the initial search were supplemented by five additional reports 
identified by hand-searching citation lists (Ray, 1973, Saito et al., 1983, Al 
Balushi et al., 2013, Naito, 1986, Reber et al., 1987). Thirty-five studies were 
finally included in this narrative synthesis.  Figure  4.1 summarizes these 
steps.  
Familial clustering 
 
Nine studies (classified as case reports, case series, and epidemiological 
studies) present evidence for familial clustering of cholesteatoma (Ray, 
1973, Lipkin et al., 1986, Podoshin et al., 1986a, Naito, 1986, Homøe and 
Rosborg, 2007, Prinsley, 2009b, Al Balushi et al., 2013, Landegger and Cohen, 
2013, Djurhuus et al., 2015b).   
 
The author describes clustering of cholesteatoma in 15 families in East 
Anglia (Prinsley, 2009b), with more than one generation affected in some 
families.  It seems likely that all or most of these cases were of acquired 
cholesteatoma, and the vertical pattern of transmission suggests an 
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autosomal dominant inheritance pattern, with incomplete penetrance.  
Homoe describes a nuclear family with several members affected by 
acquired cholesteatoma (Homøe and Rosborg, 2007) and Naito describes 
dizygotic twins who are both affected; these findings are also consistent with 
an autosomal dominant inheritance pattern with incomplete penetrance 
(Naito, 1986).  (Landegger and Cohen, 2013, Lipkin et al., 1986, Ray, 1973) 
all describe parents and siblings within a single nuclear family with 
congenital cholesteatoma and (Al Balushi et al., 2013) describes 
monozygotic twins affected by cholesteatoma, suggesting that risk of 
congenital disease may also be transmitted in an autosomal dominant 
manner. The identification of affected siblings in a single generation 
[horizontal transmission] could also be interpreted as a recessive pattern of 
inheritance (Naito, 1986, Ray, 1973, Al Balushi et al., 2013, Landegger and 
Cohen, 2013) in some families. 
 
Two epidemiological studies, a cross-sectional study conducted in a Kibbutz 
(Podoshin et al., 1986a) and a recent Danish cohort study of orofacial cleft 
(Djurhuus et al., 2015b), present further evidence of a role for heritable 
factors in the development of cholesteatoma.  
 
No studies reporting familial clustering have undertaken DNA analysis of 
affected members. The study presented in this thesis is probably the first 
attempt anywhere in the world to do this. 
 
In addition to these eight studies, there was a cross-sectional survey of 
cholesteatoma incidence in 5637 patients undergoing treatment for chronic 
suppurative otitis media (CSOM) in Nepal (Thornton et al., 2011), of whom 
nearly 20 % had cholesteatomas. One of the study aims was to determine 
whether ethnicity affects the frequency of cholesteatoma, and surname 
data were used to categorise participants as Indo-Caucasian (n = 4875) or 
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Tibeto-Mongolian (n = 765).  The authors concluded that ethnicity was not a 
determinant of cholesteatoma pathogenesis in this population. 
Syndromes and cholesteatoma 
 
22 case reports and epidemiological studies describe the occurrence of 
cholesteatoma in patients affected by congenital and malformation 
syndromes (Daugbjerg and Everberg, 1984, Graham and Allanson, 1999, 
Lipkin et al., 1986, Worley et al., 1999, Djurhuus et al., 2015b, Lau et al., 
1988, Bacciu et al., 2005, Saito et al., 1983, Suzuki and Ohtani, 2004, Büchner 
and Itin, 1992, Herrmann et al., 2005, Jin et al., 2010, el-Sayed et al., 1997, 
Colnaghi et al., 2006, Mann et al., 2014, Bergamaschi et al., 2008b, Hall et 
al., 2009, Lim et al., 2014, Kornblut et al., 1982, Iino et al., 1987, Vaglio et al., 
2008); several of which have a known underlying genetic aetiology.  
 
Some of these reports are of cholesteatoma occurrence in a single case of a 
particular syndrome, for example Beckwith-Wiedemann syndrome, 
Granulomatosis with Polyangiitis, Nager syndrome, primary ciliary 
dyskinesia, Tolosa-Hunt syndrome, Treacher Collins Syndrome, and Wolf-
Hirschhorn Syndrome.  Single occurrences of a disease, whether associated 
with a syndrome or not, are susceptible to publication bias and so do not 
add to understanding of disease risk in isolation. Also Tolosa Hunt syndrome 
and Granulomatosis with Polyangitis are  not generally regard as inherited 
conditions, rather acquired inflammatory conditions of unknown cause. 
 
There are three reports of congenital cholesteatoma in Branchio-oto-renal 
syndrome, an autosomal dominant disease characterised by malformation 
of the outer, middle and inner ear, the pharyngeal arches, and sometimes 
the kidneys.  The  author has as patients two sisters  with this syndrome who 
each have cholesteatoma. 
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Case series document an increased risk of acquired cholesteatoma in 
microtia, a malformation of the pinna that has poorly understood aetiology, 
but can be associated with other craniofacial malformation. Acquired 
cholesteatoma is also described in series of patients with Down syndrome 
[trisomy 21], Turner syndrome [45X] and cleft palate [multiple and complex 
genetic aetiology].  It should be noted that each of these latter syndromes is 
also known to be associated with an increased risk of COME (Bhutta, 2013a), 
and  these studies  have not evaluated whether the increased risk of 
cholesteatoma actually relates to the higher incidence of COME in these 
syndromes which is in itself a risk factor for cholesteatoma, or whether the 
increased risk is over and above this.  
 
There were three reports of other otological pathology in association with 
cholesteatoma.  One case report describes a 69 year old male diagnosed 
with a putatively congenital cholesteatoma, co-existent with a vestibular 
schwannoma in the contralateral ear (Ogungbo et al., 2002). A second case 
reports bilateral congenital cholesteatoma associated with anomalies of 
both ossicular chains in a 15 year old male (Suetake et al., 1991). The third 
is a case control study of radiological anatomy of the cochleovestibular 
apparatus in 31 patients with congenital or acquired cholesteatoma (Propst 
et al., 2008), with findings of abnormal vestibular anatomy, including dilated 
endolymphatic fossa, large vestibular aqueduct, and hypoplastic vestibule.    
 
Candidate genes and variants 
 
Just two published studies of DNA-based laboratory investigations of 
particular gene sequences considered in association with the cholesteatoma 
phenotype were identified in the review. One is a case report of a 6 year old 
boy with a congenital cholesteatoma who was shown to have a deletion in 
the APC tumour suppressor gene (Shaoul et al., 1999). A single case report 
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is of limited relevance. The other is a candidate-gene association study of 
polymorphisms of the GJB2 and GJB6 loci that encode connexins (James et 
al., 2010) in a cohort of 98 children undergoing surgery for cholesteatoma. 
GJB2 “may be more common” in a minority of children with cholesteatoma 
and there is a known association with neural deafness. This is much too small 
a study for useful gene association conclusions to be drawn with essentially 
negative findings{14/96 children}. Neither study was considered useful in 
the design of the Genetics of Cholesteatoma study. 
 
Risk of bias and quality assessment 
 
Only a small body of literature that was relevant to questions about a 
heritable component for cholesteatoma aetiology was identified. Many of 
the studies provide some indirect evidence only, given that the authors’ 
objectives were to describe cholesteatoma management or associated 
environmental factors. 
 
Most of the studies identified in the literature search, and described here, 
are case reports and so represent the lowest level of evidence. Case reports 
were automatically categorized as level 5 .The remaining observational 
studies include case series, cross-sectional surveys, case-control studies and 
cohort studies; each of these manuscripts was reviewed to define the level 
of evidence presented; STROBE and STREGA guidelines were referred to in 
classifying the quality of the methodology used in the case-control and 
cohort studies. The level of evidence ranged from 4 [for low quality case 
control studies, surveys and case series] and 2b for a high quality cohort 
study (Djurhuus et al., 2015b, Lim et al., 2014) [see tables in the published 
article which is  in the Appendix] 
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Discussion 
 
This is a systematic review to explore the constitutional genetics of 
individuals affected by cholesteatoma. Data from 35 published studies about 
familial aggregation of disease; its association with congenital syndromes; 
and genes that were directly analysed in patients with cholesteatoma has 
been synthesised. 
 
Heritability 
 
The published evidence about the heritability of acquired and congenital 
cholesteatoma is summarised.  Although there are few case reports and case 
series that show two or more affected first degree relatives, there are  
nevertheless some compelling individual observations, including affected 
monogenic (Al Balushi et al., 2013) and digenic twins (Naito, 1986, Prinsley, 
2009b), a vertical pattern of inheritance within families (Lipkin et al., 1986, 
Homøe and Rosborg, 2007, Prinsley, 2009b), and high rates of bilateral 
disease in affected families (Naito, 1986, Prinsley, 2009b). It is possible that 
for such families cholesteatoma arises because of causative alleles of major 
phenotypic effect.  
 
To explore any genetic architecture for sporadic cholesteatoma cases, 
genome-wide-complex-trait-analysis could be used, but large cohorts of 
study participants would be needed to provide sufficient power to identify 
candidate alleles (Yang et al., 2011).  As outlined in the introduction, 
acquired cholesteatoma often arises against a background persistent 
mucosal inflammation after a period of chronic otitis media with effusion 
(COME), and therefore any genetic study for inherited risk factors might be 
expected to identify markers already associated with COME 
pathophysiology. In childhood, COME has an estimated heritability of 71% 
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(Casselbrant et al., 1999) and Bhutta et al. have previously reviewed 
candidate genetic variants that may be risk factors for that condition 
(Bhutta, 2013b). 
 
Observations about the familial aggregation of phenotypes are often 
followed by more discriminating epidemiological methods to distinguish the 
influence of heritability from shared environments. Because cholesteatoma 
is so rare, a classical twin-study has not been conducted and is not feasible. 
However, a study or register to collect data about the incidence of bilateral 
disease in an individual in comparison to the general disease incidence and 
the coincidence of disease in dizygotic twins might be able to provide 
information about a genetic component to the aetiology of cholesteatoma 
in a manner analogous to studies of monozygotic versus dizygotic twins.  
 
Congenital syndromes 
 
Several lines of evidence suggest that variants in genes regulating ear 
embryogenesis and tissue architecture also increase the risk of 
cholesteatoma.  For example congenital cholesteatoma is more common in 
the malformed ears of people with branchio-oto-renal syndrome. The most 
common cause of this syndrome is a mutation in the gene EYA1, which is 
thought to play a role in transcriptional regulation during embryogenesis.  
Acquired cholesteatoma occurs more often in individuals with microtia.  
Radiological evidence of vestibular malformation has been described in 
some of those with congenital or acquired cholesteatoma.  Hence, some of 
the genes regulating ear formation may also be candidates for association 
with non-syndromic congenital or acquired cholesteatoma. 
 
Two studies independently discussed associations for cholesteatoma with 
Focal Dermal Hypoplasia [FDH] (Büchner and Itin, 1992, Reber et al., 1987), 
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which is also multisystem disorder that can be associated with facial 
asymmetry and dysmorphology. Mutations in the X-linked, PORCN gene 
have recently been identified as causative genetic variants for FDH; the 
PORCN locus encodes a regulator of Wnt cell-signalling (Grzeschik et al., 
2007). 
 
The association of acquired cholesteatoma with Down Syndrome, Turner 
Syndrome and cleft palate is more difficult to disentangle, as these 
syndromes also place individuals at increased risk of COME, which often 
precedes development of cholesteatoma.  Whether these syndromes are in 
themselves associated with increased risk of cholesteatoma is difficult to 
say.  In contrast, Djurhuus et al. (Djurhuus et al., 2015b) showed a doubling 
of risk of cholesteatoma in siblings of patients with cleft palate.  This finding 
should nevertheless be taken with some caution, the associated p-value was 
0.026, which would be considered insignificant if it had been subject to 
Bonferroni adjustment due to the multiple hypothesis testing present in this 
study. A sub clinical effect on muscular activity around the Eustachian tube 
was the suggested explanation in the siblings. 
 
Gene associations 
 
Little evidence is presented in the literature about the role of particular 
genes in cholesteatoma biology because only two studies reported the 
analysis of gene sequences: a case report and a small candidate gene 
association study. The case report describes a 6 year-old boy affected by 
familial adenomatous polyposis who had cholesteatoma, and an inherited 
deletion in the tumour suppressor gene APC. The APC protein is expressed 
in many tissue types; influencing cell migration, adhesion and 
morphogenesis.  Loss of APC expression in the colonic epithelium leads to 
an imbalance of cell growth over cell death (Kinzler and Vogelstein, 1996), 
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but whether this is relevant to cholesteatoma biology is not known (Shaoul 
et al., 1999). The second study was a candidate-gene association study of 98 
children with cholesteatoma for variants in the connexin gap-junction 
encoding genes, GJB2 and GJB6 (James et al., 2010); some mutations of 
these loci are known to lead to recessive congenital deafness. Although the 
authors suggest a high frequency for some GJB2 gene variants associated 
with cholesteatoma, no conclusions can be safely drawn from this study, 
because it lacked a control population and had a small sample size, placing 
it at risk of false discovery. 
Limitations 
 
Non-English manuscripts and studies published before 1980  were excluded 
from the initial search [the earlier and/or non-English articles were 
subsequently included in the narrative synthesis because they were 
identified by hand searching citation lists]; it is therefore possible that 
relevant publications  have been omitted. 
 
The over-representation of case reports, case series and historical 
epidemiological studies is unsurprising given that cholesteatoma is a rare 
disease, but such studies provide low-level evidence in the research 
hierarchy because they are usually retrospective with incomplete data 
collection or follow up, and are subject to author bias, ascertainment bias 
and publication bias. In addition such findings may not be generalizable, and 
should be interpreted with caution, particularly with respect to theories 
about the underlying aetiology of cholesteatoma. 
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Conclusion 
 
Cholesteatoma is a complex and heterogeneous clinical phenotype.  In a 
handful of case-reports or case-series, congenital and acquired 
cholesteatoma has been shown to segregate within families in the pattern 
typical of  a monogenic or oligogenic disorder with incomplete 
penetrance. The liability threshold for the observed cholesteatoma 
phenotype could therefore depend on a combination of environmental and 
genetic factors of variable penetrance. Evidence from syndromic cases 
suggest that genes controlling ear morphology may be risk factors for 
congenital or acquired cholesteatoma formation.   
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Chapter 5 The Genetics of Cholesteatoma: Experimental 
Methods,  Results and Discussion 
 
Summary of contents 
 
This chapter describes the method by which  families with  several affected 
individuals were recruited to the pilot study. The method of collecting and 
storing the family history and drawing the family trees is explained. The 
method for extracting DNA from blood samples at the molecular genetics 
laboratory is described together with the sequencing method used at the 
Earlham Institute. The bioinformatics strategy used to identify genetic 
variants of interest is described. 
 
The  pedigrees of the recruited families are described and the results of the 
pilot sequencing and bioinformatics experiments are presented and 
discussed. 
 
 Introduction 
The human genome and its variants 
 
The human genome consists of 3 billion or so nucleotides that make up the 
DNA in all 46 chromosomes.  Exons [derived from EXpressed RegiON]  make 
up only  about  1.5% of genomic DNA which are expressed as amino acid 
sequences to form proteins. The exome is the name given to all of the exons. 
Introns refer to the large sections of DNA base sequences that lie between 
the exons. 
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Each gene has a unique internationally agreed identifier consisting of letters 
and numbers. HUGO or the Human Genome Organization Nomenclature 
Committee is responsible for this system. : https://varnomen.hgvs.org/ 
 
An rs number for Reference Single Nucleotide Polymorphism [SNP] is a 
unique number applied to each SNP. dbSNP is a resource which acts as a 
single database to identify genetic variation. 
 
GeneCardsThe Human Gene Database is a free to use comprehensive 
website that provides information on human genes by integrating genomic 
and clinical information and can be used to interrogate the genetic variants 
that are revealed:  https://www.genecards.org/ 
 
Essentially three features of code variation are sought from analysis of the 
DNA sequence.  
 
1. Variants that have a known impact on gene expression such as: 
 A duplication called a short tandem repeat [STR]. If these 
occur in regulatory or coding regions they can have a large 
effect but if they occur in intergenic regions they are less 
likely to important. 
 A deletion or a change of a DNA base at a single location 
[in/dels]. If this occurs in a coding region the whole sequence 
may be shifted known as a frame shift. This can have a big 
effect on the amino acid sequence. 
 Copy number variants occur if there is a duplication or loss 
of an entire section of DNA or even a chromosome[trisomy] 
Exon sequencing does not detect this and is not relevant to 
this study. 
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 Complex structural chromosome variants with loss or 
translocation of large sections of DNA potentially causing 
large phenotype effects. 
 Single nucleotide variants [SNV]. These are the commonest 
variants. This is change of a single base and the effect will 
depend on whether there is an effect on an amino acid. If it 
is a common variation it is called a single nucleotide 
polymorphism. Because the code contains 64 possible 
codons for only 21 amino acids there is redundancy in the 
code and many SNV have no effect on the amino acid 
sequence. 
 
2. Variants that are observed to co segregate with the phenotype are of 
interest. That is to say they are present in the affected individuals and absent 
in the unaffected relatives within a family. Non penetrance is a confounding 
factor which means that the gene variant may be present but is apparently 
not expressed in the individual. Variants that co segregate with the 
phenotype across several families are of particular interest. 
 
3. Variants that are rare in the general population studied are variants of 
interest. For example if 50 % of a population would be expected to exhibit 
the variation that is not of interest but if <1 % of the population would be 
expected to have this variant then that is very interesting. 
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Genetic mapping 
 
Before whole genome and whole exome sequencing was feasible at scale, 
the mapping and elucidation of pathogenic disease variants was a 
painstaking process. 
 
Traditionally identification of a disease causing mutation started with 
linkage analysis in a sufficient number of families. Linkage to a particular 
chromosome involves identification of  DNA polymorphic markers with 
known positions on genetic maps and observations about associations with 
the disease. Such markers may, for example, be single nucleotide 
polymorphisms [SNP] or clusters of known repeat sequences called variable 
number tandem repeats [VNTR]. This is then further narrowed with finer 
more densely packed markers to narrow the region of the chromosome 
under investigation. The closer the mutation to the marker the greater the 
chance of them appearing together. Markers such as SNP are  detected by 
hybridization to microarrays and since the completion of the Human 
Genome Project and the production of reference sequence maps it has been 
possible to directly interrogate the candidate region. 
 
Other methods of gene mapping include functional cloning if the nature of 
the molecular protein change is known and  candidate gene approaches 
which use knowledge of the function of previously isolated genes. 
 
In  families with evidence that a trait is inherited as a monogenic or 
oligogenic disorder, Next-Generation-Sequencing (NGS) studies (Ott et al., 
2015) can now be used to identify functionally significant genetic variants 
that co-segregate with the phenotype. An example from ENT surgery of the 
successful use of this technique is described in a study using NGS of patients 
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with congenital anosmia by Alkelai et al in which WES of 8 multiply affected 
families is described and in which 548 rare segregating variants were 
identified (Alkelai et al., 2017). NGS studies of rare familial phenotypes often 
reveal private [kindred-specific] mutations, but such findings, derived from 
a small number of individuals within a single family, can also be generalizable 
if they identify the genes and biological pathways that are also perturbed in 
other cholesteatoma patients.   
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Whole genome sequencing WGS compared to whole exome sequencing WES 
WGS WES 
Entire 3 billion base pair genome is 
sequenced; includes regulatory 
elements and introns 
Only 30 million bases of the 
genome sequenced but the exome 
codes all the proteins. Cheaper and 
quicker laboratory and 
bioinformatic steps 
All variants detected including large 
structural changes missed by WES 
Good for rapid detection of 
important snv and in/dels 
Costly data storage and sequencing Cheaper 
Could identify variants outside the 
exome 
Most pathological variants for 
genetic disease are snv or in/dels 
that lie in the coding regions 
Typically 5 million variants to the 
reference genome 
Typically 30,000 variants to the 
reference genome. Only a few 
hundred are rare and may or may 
not have importance 
 
 
Table 5-1 WGS v WES 
 
 
Whilst whole genome sequencing is the most comprehensive method of 
gene analysis it is also the most expensive, especially in relation to 
sequencing costs and data storage, and since most pathogenic mutations 
are thought to occur either within exons or near to exons WES was 
considered an appropriate strategy to use in the Genetics of Cholesteatoma 
project. Changes in protein expression regulating ear keratinocytes  are 
thought  likely to be revealed by WES strategy with a relatively  small chance 
of missing significant mutations. 
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Study objectives 
 
To identify genetic pathways predisposing to cholesteatoma. 
 
1 The first goal was to establish a database of multiply-affected families; to 
record their family histories [for otology and genetics]; and to collect 
biological samples from participants for DNA extraction and storage in a 
biobank. 
 
2 The second goal was to undertake whole exome sequencing of affected 
and unaffected individuals in the recruited families and to complete 
bioinformatics studies to identify candidate genetic variants that co-
segregate with cholesteatoma. 
 
Materials and Methods 
 
Study Population 
 
A simple enquiry about a family history in a patient presenting with a 
cholesteatoma has been the means by which the author has created a 
database of 38 families with 2 or more members in whom a diagnosis of 
cholesteatoma has been made over a period of 22 years of otology practice 
at 2 hospitals in Norfolk UK. The diagnosis of cholesteatoma was based on 
the author's personal clinical records in many cases and  also by inspection 
of the hospital case records. 
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This formed the population group  studied in the first pilot sequencing 
experiments described in this thesis. The British Society of Otology, which is 
a network of otologists working in the UK, and other informal personal 
networks have been used to recruit other promising families of affected 
patients throughout the country for future inclusion. The study is adopted 
by the UK National institute for Health Research which facilitates and 
supports medical research in multiple recruitment sites. 
 
Families who have been identified were contacted by letter or telephone 
and enrolled and consented by face to face contact. Arrangements were 
made to see patients and their families either in their own homes or at the 
local hospital research facility/ENT clinic as appropriate and agreed. 
 
Eligibility for recruitment to the study 
Inclusion criteria 
 
1 Patients with at least one ear affected ear by cholesteatoma and who have 
a family history of cholesteatoma. 
 
2 Families of patients in which there are one or more other affected 
individuals who agree to participate in the study by donating a biological 
sample for DNA extraction.  
Exclusion criteria 
 
1 Only one affected individual with a confirmed case of cholesteatoma in the 
family. 
 
2 Families unwilling to consent to study participation. 
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Consent and participant information 
 
The study was explained in detail and informed consent obtained. The 
participant personally signed and dated the informed consent form which 
was countersigned by a delegated member of the research team. The 
participants were presented with age appropriate information sheets 
explaining the rationale for the study, the constraints of the protocol and 
the safeguards. It was made clear to the participants that they were  free to 
decline or withdraw at any time without explanation and without prejudice 
to their medical care. Copies of the signed consent and assent  forms were 
retained by the participants and by the research team. 
 
See appendix for  consent /assent forms / patient information sheets.  
 
 
Participant Numbers for Database 
 
The numbering system to track participants incorporated the hospital site; 
& then the kindred/family; and then the individual within the family.  
The recruiting research nurse/clinician allocated these numbers.  
These site/family/individual codes were added to the Sample Number field 
at the bottom of the DNA extraction request form. 
 
Family History 
 
A family history was collected from the participant. The primary phenotype 
of interest was the diagnosis of cholesteatoma. Secondary phenotypes of 
interest were other otology disease including chronic otitis media; and 
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diagnosis of genetic disease or congenital disorders for example Down 
syndrome.  
 
For each index case/relative in the 3 or 4 generation kindred the following 
data on a proforma was collected: relationship to index case; name; date of 
birth; alive or dead (and date or year of death if applicable]; surgical 
treatment for cholesteatoma, age at diagnosis  and age at time of surgery if 
applicable, with dates of all surgical treatments unilateral or bilateral 
disease, indicating which ear/s  affected; secondary otology & genetic 
phenotypes of interest. 
 
Sketches of family history or formal pedigree diagram were recorded and  
the Phenotips software tool was used to create family tree diagrams. 
(https://phenotips.org/ (Girdea et al., 2013)) 
 
See appendix for the phenotype proforma, DNA extraction form and postal 
instructions. 
 
The computer data base recording the recruits and the code is securely held 
in the clinical research office in the hospital and can only be accessed by 
members of the research team. 
 
Biological samples and DNA extraction 
 
Blood samples from participants were collected in 3ml EDTA tubes by the 
research clinician and DNA extraction  completed using the QIAamp DNA 
Blood Mini Kit [Qiagen, UK].  All biological samples (blood and/or DNA) are 
stored in a biobank by the Department of Molecular Genetics at the Norfolk 
and Norwich University Hospital.  
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Whole Exome Sequencing  
Library preparation, target capture and sequencing method used for the pilot 
study 
 
The library construction and subsequent captures were performed using an 
amended v5.1 protocol from NimbleGen [NimbleGen 2015].  1µg of DNA 
was sheared to 300bp using a Covaris LE220 and libraries were constructed 
on a PerkinElmer silicone automation platform using KAPA HTP DNA library 
preparation kit and a bead based size selection step. 5 cycles of PCR were 
carried out and the 12 samples were combined equimolarly into 4-plex pools 
at a concentration of 1.2µg.  
 
The hybridisations were set up using NimbleGen SeqCap EZ_ Human Exome 
V3.0 bait set [Design Name: 110823_HG19_Bex_L2R_D03_EZ_HX1]. This 
bait set was designed to target selected regions using annotations as in using 
the human genome reference sequence [version GRCh37/hg19]. 
 
Each pool of DNA libraries was hybridized at 47°C for 72 hours in a verti PCR 
machine with a lid heated to 57°C.  The reaction was optimized and the 
amount of universal blocking oligos was elevated from 1µl to 2.4µl, 12µl Cot-
1 DNA was added and finally 1.2µl of pooled blocking oligos were used. The 
pull down and washes were performed on the bench and the captured DNA 
received a final 9 cycles of PCR.  The resulting libraries were tested using the 
Agilent BioAnalyser to check the quality or by a qubit fluorometer or q-PCR 
to check the quantity.  Each of the 4-plex hybridization pools were then 
pooled together to form a 16-plex pool for WES on an Illumina HiSeq4000 
platform with a 75bp paired end read metric.   
Next-generation sequencing,  library construction and production of files for 
bioinformatics analysis was delivered for the pilot experiments by the BBSRC 
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National Capability in Genomics [BB/J010375/1] at Earlham Institute by 
members of the Genomics Pipelines Group. 
 
Bioinformatics 
 
Variant calling, annotating, and filtering, used a bespoke pipeline or in other 
words a specially designed software programme designed to identify 
variants of interest. 
 
The WES (whole exome sequencing) computer generated readings were 
aligned to the latest human reference genome sequence.  This uses an 
alignment algorithm with the variants being identified using software called 
FreeBayes [a genetic variant detector ]. This software uses Bayesian theory 
to make predictions of probability based on incomplete data.  VCF-tools 
were used to intersect the genotype files to identify common mutations 
between the family groups. Finally functional information about the 
identified variants is available from a VEP (variant effect predictor) software 
programme. (McLaren et al., 2016) 
  
Variants that segregate with cholesteatoma across sequenced trios or sub-
groups [within each family] were determined using VCF-isec software 
(Danecek et al., 2011). These variants were stratified by their minor allele 
frequency and compared with data from the Exome Aggregation Consortium 
(Lek et al., 2016) in order to exclude common variations that likely to be non-
pathogenic. Candidate variant lists were compiled for further analysis with 
reference to genes and gene families identified in our systematic literature 
review (Jennings et al., 2017). 
The bioinformatics analysis of the VCF files was completed by Dr Dan Swan, 
formerly head of the Genomics Pipelines Group at the Earlham Institute, 
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Norwich; and currently Bioinformatics Delivery Manager at NCIMB, 
Aberdeen. 
Ethics & Research Governance 
 
The study was granted ethical approval by East of England Cambridge 
Research Ethic Committee REC 16/EE/01311   after application using the 
Integrated Research Application System IRAS  ID  186786.  
See appendix  
 
All members of the research team are trained in Good Clinical Practice NIHR 
CRN and are familiar with standard research governance protocols. 
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Flow chart illustrating outline of study protocol 
 
 
 
 
Figure 5-1 flow chart for GoC protocol 
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RESULTS OF THE PILOT STUDY 
 
In phase 1 of the pilot study a biobank with linked database has been 
established. A whole exome sequencing strategy and bioinformatics pipeline 
have been developed to investigate the genetic architecture of familial 
cholesteatoma.  Preliminary filtering has identified candidate variants that 
could have an impact on the disease process. 
Recruited individuals and families  
 
66 individuals from 13 East Anglian families have been recruited to the 
Genetics of Cholesteatoma study between November 2016 and April 2018. 
31 are definitely affected with cholesteatoma mostly operated by the 
author. 
 
The table shows the recruited individuals and families. Each colour 
represents a recruited family. 
 
Index/relationship Study no Uni, Bilateral, N/A 
Index case GY0101 Unilateral 
Sister GY0102 Bilateral 
Sister GY0103 N/A 
Brother GY0104 N/A 
Husband GY0105 N/A 
Neice GY0106 Bilateral 
Sister-in-law GY0107 N/A 
Son GY0108 Unilateral 
Index case GY0201 Bilateral 
Wife GY0202 N/A 
Sister GY0203 N/A 
Brother GY0204 Unilateral 
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Brother GY0205 Bilateral 
Son GY0206 Bilateral 
Index case GY0301 Bilateral 
Brother GY0302 N/A 
Brother GY0303 Bilateral 
Mother GY0304 N/A 
Father GY0305 N/A 
Brother GY0306 Unilateral 
Brother GY0307 N/A 
Index case NN0401 Bilateral 
Sister (twin) NN0402 Unilateral 
Brother NN0403 Unilateral 
Mother GY0404 N/A 
Father GY0405 N/A 
Index case GY0501 Unilateral 
Daughter GY0502 Unilateral 
Father GY0503 N/A 
Husband GY0504 N/A 
Sister GY0505 Bilateral 
Index case GY0601 Bilateral 
Wife GY0602 N/A 
Daughter GY0603 Unilateral 
Daughter GY0604 N/A 
Daughter GY0605 N/A 
Index case GY0701 Unilateral 
Husband GY0702 N/A 
Daughter GY0703 Unilateral 
Index case GY0801 Bilateral 
Daughter GY0802 N/A 
Brother GY0803 Unilateral 
Wife GY0804 N/A 
Index case GY0901 Bilateral 
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Husband GY0902 N/A 
Daughter GY0903 N/A 
Son GY0904 Unilateral 
daughter GY0905 N/A 
Index case GY1001 Unilateral 
Mother GY1002 N/A 
Auntie/Uncle GY1003 Unilateral 
Grandmother GY1004 N/A 
Index pt NN5001  Bilateral 
Patients mother NN5002 N/A 
Index pt NN5101 Unilateral 
Daughter NN5102 N/A 
Son NN5103 N/A 
Daughter NN5104 Unilateral 
Father NN5105 N/A 
Mother NN5106 N/A 
Cousin NN5107 N/A 
Index pt NN5201 BIlateral 
Twin NN5202 Unilateral 
 Mother NN5203 N/A 
 Sister NN5204 N/A 
 Sister NN5205 N/A 
 Sister NN5206 N/A 
 
Table 5-2 List of recruits to the Genetics of Cholesteatoma Study 
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The pedigree diagrams illustrate the recruits  
 
The shaded symbols represent individuals affected with cholesteatoma and 
have all been treated surgically. The arrow is the index case.  The asterisk 
represents an individual who has been recruited to the study. Only one 
individual affected with cholesteatoma from family GY02 declined 
recruitment.  
 
The history of mastoid surgery for cholesteatoma is included with the age at 
operation if known. The disease is recorded as unilateral or bilateral. 
 
 
 
 
 
 
Figure 5-2 Family NN04.  Almost certainly a dominant trait. All 3  children are affected and 1 of the 
identical twins has bilateral disease. This family has been subjected to detailed bioinformatics since 
all of the individuals are recruited to the study. 
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Figure 5-3 Family GY01. There are 4 affected individuals with 2 bilateral cases and an affected niece. 
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Figure 5-4 Family GY03. There are 3 affected brothers, 2 of whom have bilateral disease. 
 
 
 
 
Figure 5-5 Family GY02. Here are 3 generations with several bilateral cases. Sadly case I-2 is 
deceased. 
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Figure 5-6 Family GY05. Twins with bilateral ear disease  and 1 affected daughter. 
 
 
Figure 5-7 Family GY06. Case II-2 has unusual inherited traits. 
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Figure 5-8 Family GY07. All 3 members of this pedigree are recruited. The mother has recidivistic 
disease. 
 
 
 
Figure 5-9 Family GY08. Case 111-1 looks to be at high genetic risk of cholesteatoma. 
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Figure 5-10 Family GY09 All 5 members of this  family are recruited to the study. 
 
 
 
 
Figure 5-11 Family NN52.Identical twins only distinguished by the fact that one of them has bilateral 
disease. The mother had ear surgery as  a child. 
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Figure 5-12 Family NN50. This is the pedigree of the patient discussed in chapter 2. There are 
maternal uncles on both sides of the family with a history of cholesteatoma. This is not a classical 
autosomal dominant pattern. The ancestry on both sides is suggestive of additive genetic factors. 
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Biobank 
 
Blood samples from 66 participants were collected in 3ml EDTA tubes and 
DNA extraction was completed using the QIAamp DNA Blood Mini Kit 
[Qiagen, UK]. The protocol for DNA extraction was optimized to allow for the 
intermittent receipt of samples, the samples are now stored at -80°C on 
receipt and processed in batches. All biological samples [blood and/or DNA] 
have been stored in a biobank by the Department of Molecular Genetics at 
the Norfolk and Norwich University Hospital.  
 
Sequencing and Analysis 
 
The pilot analysis has considered primarily a dominant model of inheritance 
with variable penetrance. With a dominant mode of inheritance as our 
model, affected individuals must be heterozygous and unaffected 
individuals must be homozygous for the reference human genome sequence 
and the data are filtered accordingly. There is a need to be circumspect 
however because several generations can be affected for oligogenic and 
polygenic complex traits. There may be a threshold of genetic liability for 
affected individuals that may result from the accumulation of additive 
impacts from several or many key variants that are common within the 
families. 
 
When full bioinformatics analysis is completed several models could be 
accommodated. The pilot study considers the dominant model because of 
the preliminary nature of the dataset and so this is a study limitation at 
present. 
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The pilot sequencing study identified 95,437 candidate variants that 
segregate with the disease phenotype [using NimbleGen exome capture; 
and the Illumina HiSeq4000 platform] in this experiment on 16 DNA samples 
collected from four families. Financial constraints have thus far restricted 
the WES to 16 of the 66 samples. 
 
The performance of the exome capture on the samples was within expected 
tolerance. Mean target coverage for the exome sequence ranged from 24 
fold to 56 fold. A minimum coverage of 30 fold is generally desired and only 
two samples were below 30x mean target coverage, due to lower read 
numbers for these samples. 
 
A suggestion that there may be some common ancestry between the 
families  recruited to the study was made, and although GY01 and GY02 look 
like they could be related on the basis of the principal component analysis, 
closer inspection of kinship metrics refuted this. There was therefore no 
genetic evidence of a common ancestry between the families and of a 
“founder effect”. 
 
A number of gene variants co segregated with cholesteatoma patients in all 
of the four families. 
 
There are six genes in coding regions of the exon sequences where a variant 
is in the same gene in all four of the families but in which the variants may 
not be for the same positions at the loci. 
 
A Venn diagram reveals the overlap. Of particular note in this group are 
CCHCR1 gene variants which have associations with psoriasis and a rare 
disorder called peeling skin syndrome and DNAH9 variants associated with 
ciliary dyskinesia. 
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Figure 5-13 Venn diagram of overlapping variants. 
 
The Venn diagram generated by the Ensembl Variant Effect Predictor 
bioinformatics programme shows the overlapping variants in the four 
families for genes predicted to have a high or moderate functional impact 
both within and outside of coding regions. The six that appear in all the 
families are within protein coding regions. 
 
In addition three  non-coding gene variants were seen to co-segregate  with 
the phenotype in all of the families: Non coding DNA describes base  
sequences not translated into amino acids sequences  but which  may 
nevertheless have a role in gene regulation.  
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FAMILY NNO4 
 
Family NN04 is the only family in which all the recruits have been sequenced. 
This family of three siblings and two parents has been subject to more 
detailed bioinformatics analysis. There is also an affected maternal cousin. 
In family NN04, based on the model of dominant inheritance with 
incomplete penetrance, we found variants in 442 genes that segregate with 
cholesteatoma.  
 
Further filtering of this long list using Ensembl VEP  to  include only the rare 
co-segregating variants, with a rare allele frequency of < or = 0.01,  has 
reduced the number of candidate genes to 32. A complete data set from 
these 4 multiply-affected families and a range of genetic models  can be 
considered in the next phase of the pilot study when more sequencing data 
is available. 
 
Missense variants that both software programmes (SIFT & POLYPHEN) 
predict to be benign or non-deleterious have been removed with  the 
exception of  the DNAH6 variant rs192646174 which is predicted to be 
benign/tolerated but is in one of the genes mutated in all 4 affected families. 
  
The remaining list of 32 variants is therefore of interest. Highlighted in red 
in table 5-2 are two single nucleotide variants of greater interest  in view of 
the predicted large effect on gene expression which are  further described 
in the discussion below. 
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Table 5-3 List of Gene variants identified by the bioinformatic filters. 
 
 
Genes with co-
segregating variants in 
coding DNA in all 4 
families 
 
 
Genes with co-
segregating variants in 
non- coding DNA in all 
4 families 
 
 
Genes with co-
segregating rare 
variants (allele 
frequency ≤ 0.01) 
predicted to have 
high/moderate 
functional impact in 
family NN04 
 
 
Loss of function SNVs 
identified in family 
NN04 
rs Id used  = reference 
SNP number for the 
variant.  
ZNF717 
 
HYDIN TMC6 EGFL8 stop gain 
variant 
rs141826798 
 
PDE4DIP 
 
EIF2A TMEM150C BTNL9 frameshift 
variant 
rs367635312 
 
 
MKI67 SERP1 KTN1  
CTD-3088G3.8  HIST1H1B 
CCHCR1  DNAH6 
DNAH9  SORL1 
  CDH1 
  CCDC144NL 
  SYNRG 
  LAMA5 
  USP19 
  ZFAT 
  CSMD2 
  ATXN10 
  CLK4 
  ACTN4 
  HELZ2 
  RNF213 
  MFSD6 
  FKBP1C 
  SHANK2 
  EGFL8 
  STK31 
  IFIT2 
  FAM65A 
  TMPRSS3 
  CRYBG3 
  ZNF267 
  CCSER1 
  TNS3 
  ABCC12 
  BTNL9  
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TGIF1 
 
The long list of variants co segregating in family NN04 includes the gene 
TGIF1 [no 226] on chromosome 18. This  gene has been subject to a further 
analysis which  illustrates the bioinformatics process which can be used to 
investigate variants of possible interest.  
 
An analysis of the TGIF1 gene is presented  in figure 5-4 using images from 
the Broad Institute’s Integrative Genomics Viewer of the variant call format 
file and scans for 5 members of NN04 and the TGIF1 gene. Each individual in 
the family has been sequenced. The peaks represent the depth of the 
sequencing read overlaps and identifies the position of the variants along 
chromosome 18. The red arrow  points to variants shared by Dad and the 3 
siblings. The blue arrow points to variants inherited from Mum. 
 
Variants of the Transforming Growth Interacting Factor [TGIF1] gene are of 
interest as a candidates for this study for several reasons: 
 
 Knockout mice have conductive deafness; develop chronic otitis 
media with effusion (COME) and thickened middle ear mucosa 
(Tateossian et al., 2013). 
 A Genome Wide Association Study of children affected by COME 
identified associations between TGIF1 variants and the phenotype 
(Bhutta et al., 2017a). 
 TGIF1 variants have been associated with a second distinct 
phenotypic pathway associated with cholesteatoma: midfacial 
morphogenesis & developmental biology. 
 Haploinsufficiency [mutations in the heterozygous state which fits 
with a dominant pattern of inheritance] for  several genes including 
TGIF1 is associated with the Holoprosencephaly disease phenotype.  
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Figure 5-14 View of TG1F Exon 
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Homeodomain proteins derived from homeobox genes act as transcription 
factors binding to and controlling the activity of other genes. TGIF1 is a 
homeodomain protein that has a role in 3 signalling pathways [RA, Retinoic 
Acid; TGFβ; Wnt/β-catenin]. It acts as a transcriptional co-repressor.  The 
first paper to describe its genomic structure; its alternate splicing regulation 
and the expression pattern of the gene/protein was in 2008 by Hamid et al. 
(Hamid et al., 2008). 
 
Possibly  some of those candidate variants have an impact on Transforming 
Growth Factor TGFβ signalling and inflammatory processes known to be 
significant in chronic inflammatory and bacterial diseases of the ear? 
Transforming growth factors are also considered to be important cytokines 
in the keratinocyte cycle. 
 
Three  particular TGIF1 mutations were identified by the bioinformatic 
programme  but closer scrutiny of these  variants  makes it unlikely that  they 
are of great importance in this family. 
 
rs11571510  
 
This frameshift mutation identified in the first bioinformatics is very 
common [allele frequency = 0.43] and it occurs in sequence upstream of the 
atg translation initiation site and is therefore not in the protein coding 
sequence. This means it is not expected to have any functional impact on 
gene expression. Two of the variants were carried by all three children and 
by Mum.  
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rs2229337  
 
This variant definitely lies in the coding sequence.  However it is a 
synonymous SNV and so not of interest functionally. 
 
rs2229333   
This is present in the undisputed coding region in the last [G8/H11] exon. 
European allele frequency 0.06, ~ 1/ 17 people carry it so it is not very rare 
but could be contributory given that it is a missense mutation resulting in a 
proline to leucine substitution [P163L].  
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Summary of sequencing findings 
 
The aim of the pilot study was to develop a bioinformatics “pipeline” to: 
 
 Distinguish gene variants from the reference human genome 
sequence. 
 Interrogate and filter the variants with respect to predicted impact 
and disease associations. 
 
95,437 variants were identified in 16 individuals from four families. Variant 
filtering, using pedigree analysis, identified 442 candidate genes. Variant 
effect prediction has narrowed this to a small number of genes of interest 
further identified as having possible disease associations. 
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Discussion 
Introduction 
 
The GOC project really began with a clinical observation made in 1996.  A 
record of patients presenting with a family history of cholesteatoma was 
initiated. Over the years a series of families has been gathered which has 
formed the basis of the GOC pilot study. 
 
The report in the Journal of Otology and Laryngology in 2009 (Prinsley, 
2009a)stimulated interest and encouragement from colleagues and in time 
it became feasible to envisage DNA sequencing for such families. Until 
recently genomic technology made it possible to look for “causative 
mutations” in only one segment of a gene at a time which greatly limited the 
time and volume of the technique. Next generation sequencing makes it 
possible to sequence millions of fragments of DNA simultaneously and 
massively increases the scale and speed of genetic science. Whilst initial 
sequencing of the human genome took more than 10 years and cost £2bn, 
the genome can now be sequenced for £700 and takes a few days.(Turnbull 
et al., 2018) 
 
In 1996 in Norwich there was no Medical School and no University Hospital. 
The Norwich Research Park was devoted largely to agricultural sciences at 
The John Innes Institute. Since then the situation has changed completely. 
There is a new University Hospital and a Norwich Medical School.  The 
Earlham Institute (formerly called The Genome Analysis Centre or TGAC) has 
been constructed at the research park. Together with my supervisors, Dr 
Barbara Jennings and Professor Carl Philpott at the University of East Anglia, 
we have assembled a team capable of undertaking this project. 
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The project presented in this thesis is a pilot study to demonstrate the 
feasibility of the method that has been used to collect family information 
from individuals with cholesteatoma, extract blood for DNA analysis, carry 
out Whole Exome Sequencing and perform Bioinformatics. The study has 
attracted the attention of otologists throughout the UK and has been 
registered on the NIHR portfolio which facilitates and supports recruitment 
of patients and families for research in the NHS. The research team intends 
to expand the study and to recruit more patients and families for sequencing 
as the search for genetic variants widens. 
 
Collection of pedigrees and blood samples 
 
The scientific advances which have made the WES study possible are quite 
extraordinary but the fundamental task of the geneticist to collect family 
histories and recruit individuals for scientific study remains one of  the most 
difficult tasks in a project of this sort.  
 
Many of the patients had previously spoken about the possibility of a future 
DNA study and it was not a surprise when they were approached by the 
research nurse for recruitment. The recruitment of unaffected near relatives 
has been helped by the good relationships that have built up with many of 
the patients and their families and, in keeping with other genetic studies, 
there has been a genuine enthusiasm within the families to help with this 
study. The patients and their relatives are themselves as puzzled as anyone 
as to what has caused this ear disease which makes them  deaf and for their 
ears to continuously weep. Having said that the diligence with which the 
research nurses have carried out this task is not to be underestimated and 
is hugely appreciated. 
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The patient information sheets and consent and assent forms were 
approved by the research ethics committee have been simple to use. 
 
For small children, and for individuals reluctant to have a blood sample, 
salivary swabs are available but these have not been used in any of the 
recruits reported here and so far all the DNA has been extracted from blood. 
It is easier to extract reliable quality and quantity of DNA for analysis from 
blood than from saliva. 
 
Database 
 
A secure data base held in the research office of the James Paget University 
Hospital was used to reconcile the family history data with the samples sent 
to the molecular pathology laboratory at the Norfolk and Norwich University 
Hospital. As the project expands to incorporate other recruitment sites 
outside of Norfolk this is no longer practical. A web database using Research 
Electronic Data Capture (REDcap) has been developed in collaboration 
with the Clinical Trials Unit at the Norwich Medical School to enable the 
family history and patient identifiable data to be securely entered at the 
recruitment site. This will then be accessible to the research team 
reconciling the samples for analysis with the individual family histories and 
patient data. 
 
 
The family pedigree charts when presented as a group are quite striking. It 
is perhaps surprising that this observation has not been more often reported 
previously. A condition which occurs in about 1 in 10,000 individuals per year 
would not exhibit a random familial pattern and therefore the family trees 
are in themselves compelling supporting evidence of a genetic causation. 
The apparent pattern of inheritance guides the individuals selected for DNA 
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sequencing and also the bioinformatics strategy. In the pilot study only a 
dominant model for an allele with a major or moderate impact has been 
considered to date, coupled with incomplete penetrance. But an oligogenic 
or polygenic mode of inheritance, with the cumulative effect from many 
alleles, could be revealed by an experiment with the much larger number of 
individuals such is proposed by the study team. 
 
Only a single affected individual declined to participate in the Genetics of 
Cholesteatoma Project and for the main part the families have supported 
the study into this disease. The families reported in this pilot study have 
been local to the Norfolk hospitals and one factor that has facilitated the 
study is the fact that in this part of England there is relatively little 
“migration”.  Norfolk families tend to stay in Norfolk and it is common for 
the author to have treated several generations of the same family. There are 
however several individuals of great interest who are not local and it is the 
intention of the research team to recruit these family members as the 
project expands. 
 
Some of the families in the database which include several affected children. 
In the pilot study none of the children have so far been recruited. The 
protocol incorporates salivary sampling for DNA sequencing and an 
experiment to test the quantity and quality of the DNA obtained by this 
method is planned in the second phase of the study. 
 
 
Sequencing 
 
The aim in the pilot experiment was to sequence a batch of DNA samples 
from study participants to establish a sequencing and bioinformatics 
protocol. The DNAs were selected after ranking them for quality before 
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library construction; they came from affected & unaffected participants 
across four families. The DNA obtained from the blood samples was of 
sufficient quantity and quality for sequencing.  
 
Gene variants co segregating with the cholesteatoma phenotype within and 
between the four families in the pilot experiment are variants of interest. 
Variants that are rare within a matched general population are also variants 
of interest. The impact of the variant is also significant since even a single 
nucleotide change may be biologically important. The bioinformatics 
software used in the experiment is able to sift the variants into those of high 
or moderate functional impact. The software also enables the samples to be 
filtered according to patterns of inheritance suggested by the family tree.  
With a dominant mode of inheritance as our model, affected individuals 
must be heterozygous and unaffected individuals must be homozygous for 
the reference human genome sequence and the data are filtered 
accordingly. 
 
In the families that are reported in this pilot study cholesteatoma self-
evidently exhibits a familial trend. The question of the contribution of 
genetics to this fact is the subject of this enquiry. Genetic architecture seeks 
to define the genetic contribution to human traits and diseases (Timpson et 
al., 2018). The genetic architecture refers to all of the genetic influences on 
a phenotype, the magnitude of the effect, the frequency of the effect and 
the interaction with the environment. In classical genetics a disease may be 
regarded as monogenic if caused by a single gene, oligogenic if caused by a 
few genes, or polygenic if caused by many genes. More recently an 
omnigenic concept has been developed by which is meant there are many 
possible small genetic effects within a diseased cell that are cumulative and 
sufficiently interconnected to result in the disease phenotype. In this theory 
mutations that are remote from the phenotypic biology might be 
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important.(Boyle et al., 2017). A pilot study such as this is designed to test if 
it is feasible to use a whole exome sequencing approach to search for genetic 
variants co segregating with the phenotype and this has been achieved in 
the population that has been recruited. 
 
The cause of cholesteatoma 
 
Despite the existence of many theories the cause of the disease remains 
unknown.  A genetic component is probable and certainly the  identification 
of a genetic basis for the disease could  have a role in diagnosis, therapy and 
prognosis.  
 
Much of the literature about the cause of the disease presents studies and 
audits of surgical series and of histopathological analyses (Louw, 2010). 
There are a number of well described histopathological mechanisms of 
abnormal epithelial migration but the fundamental cause is yet to be 
elucidated. DNA studies  using microarrays of surgical specimens matched 
with post auricular skin as a control examine  molecular pathways  and gene 
expression that show altered regulation in cholesteatoma cells (Klenke et al., 
2012b). Microarrays rely on hybridization probes of known sequence 
(Kahvejian et al., 2008) or in other words we can only look for mutations that 
are known to exist. Such studies have resulted in considerable conjecture 
about cholesteatoma causation.  The Genetics of Cholesteatoma  Project has 
adopted a completely different approach studying the whole exome 
sequence of affected and unaffected individuals in families in which the 
disease is segregating. This investigation seeks germ line rather than somatic 
mutations such as might be revealed by a study of the cholesteatoma tissue.  
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The literature review  (Jennings et al., 2018) carried out as part of the project   
suggests a genetic component in causation although the published evidence  
is really not extensive.  
 
The discovery of DNAH9 variants overlapping within the four families  was 
exciting because ciliary motility disorders are implicated in chronic sinus and 
middle ear disease and because DNAH9 variants have a known  association 
with ciliary dyskinesia.   HYDIN variants identified in non-coding co-
segregating genes may also be relevant  in view of the role  this gene is also 
known to play in ciliary motility disorders.  
 
The tympanic membrane can be considered to be specialized skin. Might  
cholesteatoma have  more in common with general dermatological 
disorders than is usually thought to be the case?  Variants in CCHCR1 were 
discovered co-segregating  with cholesteatoma in all of the four families so 
far sequenced  and these are known to be important in psoriasis which is 
very common  and peeling disease of the skin which is very rare. 
 
Within the group of 32 variants revealed by the bioinformatics in family 
NN04 are EGFL8 which is a stop gain mutation with an allele frequency of 
0.0026 and BTNL9  which is a frameshift with an  frequency of 0.0036. Both 
variants are predicted to be of high impact. 
 
GeneCards describes the location of Epidermal Growth Factor-Like Protein 
8  EGFL8 on chromosome 6 with a size of 3.703 bases on the cytogenic band 
6p21.32. Associated diseases include ischaemic bone disease. EGFL8 is 
highly expressed in the skin. Interestingly, the stop-gain variant in EGFL8, 
rs141826798, has recently been reported to be significantly associated with 
psoriasis in the one of the disease traits recorded for the UK Biobank 
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participants(Emdin et al., 2018). For both psoriasis and cholesteatoma, there 
is altered keratinocyte proliferation and differentiation.   It is possible that 
EGFL8 variants have pleiotropic effects and/ or that there is a common 
biological driver for these pathologies. 
 
GeneCards describes the location of the  Butyrophylin Like 9 gene BTNL9 
on chromosome 5 with a size of 21,299 bases on the cytogenic band 5q35.3. 
It mediates pathways related to the innate immune system. 
 
Guidelines for the analysis of sequencing variants associated with Mendelian 
traits in clinical settings are not directly applicable to research but they do 
present a useful variant classification system (Richards et al., 2015). Given 
the uncertainty inherent in filtering sequence data, individual variants are 
classified in one of five possible ways by clinical genetics laboratories: 
1. Pathogenic 
2. Likely pathogenic 
3. Uncertain significance 
4. Likely benign  
5. Benign 
The pilot genetics  of cholesteatoma study has discovered  two rare, loss-of-
function variants in genes that co-segregate with the phenotype.  These 
variants of the genes EGFL8 and BTNL9 have not been previously reported 
to be associated with cholesteatoma and there are no published studies that 
demonstrate that the variants are significant with respect to protein 
function. It is appropriate to refer to rs141826798 (g.32134395C>G) and 
rs367635312 (g.181050254delC) circumspectly as variants in genes of 
uncertain significance. 
 
 
Epidemiological studies of cholesteatoma identify the association of chronic 
otitis media with effusion. The fact that TG1F variants were found in the pilot 
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study somewhat intriguingly fits with the genome wide association study 
recently published by Bhutta et al (Bhutta et al., 2017b). Although the 
variants found in TGIF1 seem unlikely to be  significant  at this point, 
epidemiological associations with developmental disorders of the cranial 
development such as cleft lip and palate are well described (Spilsbury et al., 
2013) and so the finding of co segregating TGIF1 variants associated  with 
skull dysmorphology is also notable. 
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Beyond the pilot study and next steps for the Genetics of Cholesteatoma 
Project 
 
The pilot study was conceived to demonstrate that the research team could 
establish a protocol to collect family pedigrees, extract and sequence DNA 
and perform bioinformatic analysis. It was necessary to check that DNA of 
sufficient quality could be obtained to allow accurate sequencing to 30 x 
coverage. Funding constraints meant that only 16 WES were obtained to 
date but the results of the pilot will be used in future funding grant 
applications. The price of WES and bioinformatics is falling with recent 
quotes [November2018] at £290 for WES and £100 for associated 
bioinformatics. 
 
The research team continues to recruit participants and extract DNA for 
storage in the Biobank. Additional resources will be sought to complete the 
WES on the first four families and to produce additional variant call files for 
subsequent bioinformatics analysis. 
 
The  Biobank will grow to become a research resource for future 
investigation. Additional recruitment sites around the UK are planned.  The 
project needs a formal  database and a REDCap  system has been 
developed for secure recording and storage of participant phenotypes and 
sample processing. The associated epidemiological questionnaire which has 
used  social media is now the largest NIHR ENT study presently recruiting 
and is revealing fascinating data about family history in cholesteatoma 
patients worldwide. 
 
A laboratory protocol for the non-invasive and remote collection of DNA 
samples using mouth swabs will be devised and the  extracted DNA will be 
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tested for quality and quantity by comparing with at least one participant’s 
blood DNA. 
 
The research team plans to publish the findings of the pilot experiment  in  
an open-access journal and  to develop Research Councils UK applications 
for a  project grant. 
 
If a constitutional explanation for cholesteatoma is established then a 
number of research opportunities suggest themselves. Might recurrence be 
more likely in patients with a family history and is bilateral disease more 
common if there is a genetic predisposition? It is likely that such families are 
the best place to start looking for important variants with moderate and or 
major functional impacts. Some genes are  known to be associated with skin 
disorders and chronic inflammatory conditions of the ear in children. What 
might be the association of these genes with “cholesteatoma genes”? 
 
  
  
 
 
141 
Personal reflections on the Genetics of Cholesteatoma project  
 
This project has been a source of professional fascination  for me and I have 
learned the way in which a medical research project  of this type is 
established, organized and performed. The importance of team working has 
been very  clear to me and I anticipate that the team will grow as the project 
expands and recruits more widely. I have learned about the need to develop 
distinct study protocols, the difficulties of grant applications and have 
understood the working of the research ethics system. Indeed one of the 
early challenges was to represent the team before a rather intimidating 
research ethics committee in Cambridge. 
 
I have  learned about basic molecular biology and the science of genetics 
and something also of  the laboratory techniques, the sequencing and  the 
bioinformatics that have been used.  I was directed to the Future Learn 
initiative of  the Open University which has been an excellent resource for a 
“mature” postgraduate student such as myself. 
 
I have presented the project nationally and internationally and this too has 
been a new venture for me. 
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Chapter 6 Conclusion 
 
This thesis has described the work which has been done to establish the 
Genetics of Cholesteatoma Project in Norfolk. 
 
Cholesteatoma remains an enigma.  Not a neoplasm, not an infection, not a 
simple inflammatory process but a rather singular pathology with features 
of all three. The surgical pathology and epidemiology of the Norfolk patients 
is broadly in keeping with the descriptions in the surgical literature and can 
be regarded as  a representative group of patients, but the observation of 
familial clustering is really quite striking and it is surprising that this has not 
been previously more widely reported.  These Norfolk families have formed 
the basis of the pilot investigation.  
 
The protocol for the collection of family pedigrees and the extraction and 
sequencing  of DNA has been defined by the research team. The 
bioinformatics which has been possible on the first 16 sequenced DNA 
samples has revealed a number of intriguing genetic variants, both between 
the affected individuals within the 4 families, and within the family NN04 
which is the only completely recruited family so far sequenced. 
 
It is likely that the genetic architecture of cholesteatoma will be further 
revealed as the Genetics of Cholesteatoma Project expands. The costs of 
DNA sequencing are continuing to fall and the speed and complexity of 
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bioinformatics computing is improving rapidly. The project which is adopted 
by the NIHR in the UK NHS is set to recruit additional families from several 
sites across the country as resources develop. 
 
This project arose as a result of basic curiosity. What is the reason for the 
familial clustering of this rare ear disorder? If a genetic basis could be 
discovered then it is possible to imagine that the biochemical pathways and 
cell signal systems which are presumed to control tympanic membrane cell 
migration could  also be better understood with considerable potential 
clinical relevance. A gene panel consisting of variants known to be 
associated with cholesteatoma could be constructed and  then used for 
patients presenting with CSOM to predict cholesteatoma before it develops. 
Such a genetic screen would be inexpensive, simple to use and could  have 
significant clinical application. 
 
Experienced otologist know that there are some patients with 
cholesteatoma who seem to do badly and some  patients who seem to do 
well irrespective of the operations which are performed.  An early 
understanding of the constitutional  nature of a patient presenting with a 
cholesteatoma  might inform the timing and the nature of surgical 
intervention. Also as the project develops  there are plans to investigate the 
genetic differences between single sided and bilateral cholesteatoma since 
patients with bilateral disease may have a constitutional risk of the disease 
with a genetic basis. Early identification of this has potential to prevent 
deafness. 
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 Proforma for collecting ENT history and family history 
 
ENT-Focused Family History Questions & Proforma  
Phenotypes of Interest = Diagnosis and surgical treatment for 
cholesteatoma. Secondary phenotypes: 1.Glue-ear treated with grommets 
2.Hearing problems in childhood 3.Diagnosis of Genetic Disease/Congenital 
Disease. 
For each relative in the 4 generation family tree we are seeking the following 
information/asking the following questions:  
1. Name 
2. Date* of Birth 
3. Alive or Dead (+ date* of death if applicable) 
4. Has he or she had surgical treatment for cholesteatoma 
5. Age at diagnosis 
6. Age at time of surgery (may be more than one episode; please record 
dates* of all surgical treatments) 
7. Ask if one ear, or both ears, were affected. Indicate with a tick which ear 
(L and/or R) was/were affected. 
8. Ask if he or she was affected by other phenotypes of interest (glue ear 
treated with grommets; hearing problems in childhood; or a diagnosed 
genetic/congenital disease) and make note of any details about disease 
management including the number of ear surgeries. 
*date: use year of birth/death if more precise date is not known. 
Index Case** 
Q1 
Q2 
Q3 
Q4 
Q5 
Q6 
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Q7. L R 
Q8 Notes 
 
 
 
Recording data for individuals in 4 generations: 
** Other titles for each table: Mother (of index case); Father; Mother’s 
Mother; Mother’s Father; Father’s Mother; Father’s Father; 
Brother/Sister; Child (of index case); Child of Brother; Child of 
Brother/Sister  
 
Q1 
Q2 
Q3 
Q4 
Q5 
Q6 
Q7 L R 
Q8 Notes 
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Form to accompany blood samples to the pathology laboratory  
 
GOC STUDY 
 
Study of the Genetics of Cholesteatoma. 
 
Send to Pathology Reception, NNUH. 
 
Sample for Molecular Genetics at Norfolk and Norwich Hospital. 
Contacts are Gavin Willis or Katy Smith ex. 3068 or 2420. 
Note for Pathology Reception: Please don't book on to LabTrak; samples to 
go directly to Molecular Genetics. 
 
Name…………………………………………………………………………………… 
 
Hospital Number……………………………………………………………………… 
 
Date of Birth…………………………………………………………………………… 
 
 
By adding my initials to the box below, I confirm that: 
 
Participant consent form has been completed and archived for this study. 
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Name of Nurse/Doctor who collected sample 
____________________________ 
 
Signed ____________________________     Date _____________________ 
 
Laboratory Use: 
 
Date of receipt               ___________________________ 
  
Date of Storage             ___________________________ 
 
Date of DNA extraction___________________________ 
 
Sample number              ___________________________  
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Postage of Samples for GoC Study 
 
 
Address to send samples to : FAO Dr Gavin Willis, Principal Clinical 
Molecular Geneticist, Department of Molecular Genetics, Norfolk 
and Norwich University Hospital, Norwich NR4 7UY. 
The following advice has been developed using the standard 
operating procedure from the Norfolk & Norwich University Hospital 
for the postage of non-urgent pathology specimens. But the 
protocols recommended by other hospital trusts that are compliant 
with UN3373 regulations 
(http://www.un3373.com/info/regulations/ ) can also be followed.  
Several companies produce bespoke packaging and postal systems if 
your department does not routinely use suitable polypropylene 
tubes, absorbent materials or postage boxes. 
a) Packing for despatch by courier /post (inland or overseas) must be 
the responsibility of a trained person. It should not be entrusted 
to an untrained member of the clerical staff. 
b) The packing to be used must meet the UN3373 regulations. 
 
Pathological material must be sent by First Class Letter Post only. Post 
Office regulations specifically forbid sending such material by Second Class 
Letter or Parcel Post. The properly packed article is officially described as a 
‘packet’. 
(i) The specimen must be in a securely closed container, which must 
be robust and leak-proof. This is the Primary container. 
(ii) Each specimen container must be placed in a plastic bag and pad 
of absorbent material to prevent leakage in the event of damage 
to the container. There must be no glass-to-glass or plastic-to-
plastic contact. This is the Secondary container. 
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(iii) All letters and forms must NOT be placed inside with samples but 
if Marsupial bag used placed in the side pocket. 
(iv) The packed specimen must be placed in a box or case of suitably 
strong material such as fibreboard in such a way that it cannot 
move about.  
(v) The box or case must be securely closed with tape marked 
‘Pathological Specimen, Fragile Handle With Care’ and labelled 
with name and address of the sender (to be contacted in case of 
damage or leakage).  
If clip down container or polystyrene box is used they should 
finally be put in padded envelope and marked ‘Pathological 
Specimen, Fragile Handle With Care’ and senders name and 
address. In all cases a label with UN3373 on must be placed on 
package. 
(vi) The District Post Office must be notified at once if any infectious 
or potentially infectious material arrives in a damaged condition. 
The sender must be informed if an improperly packed specimen is 
received. 
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HRA Approval 
 
 
 
 
Mr Peter Prinsley 
Lowestoft Road 
Gorleston, Great Yarmouth 
Norfolk 
NR31 6LA 
 
Email: hra.approval@nhs.net 
 
 
 
 
Study title: An Analysis of the Pedigrees and Genetic Profile of Patients 
and Families of Patients with Cholesteatoma 
IRAS project ID: 186786 
Sponsor University of East Anglia 
 
 
Thank you for your request for HRA Approval to be issued for the above 
referenced study. 
 
I am pleased to confirm that the study has been given 
HRA Approval. This has been issued on the basis that 
the study is compliant with the UK wide standards for 
research in the NHS. 
 
The extension of HRA Approval to this study on this basis 
allows the sponsor and participating NHS organisations in 
England to set-up the study in accordance with HRA 
Approval processes, with decisions on study set-up being 
taken on the basis of capacity and capability alone. 
 
Letter of HRA Approval for a study processed through 
pre-HRA Approval systems 
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If you have submitted an amendment to the HRA between 
23 March 2016 and the date of this letter, this letter 
incorporates the HRA Approval for that amendment, which 
may be implemented in accordance with the amendment 
categorisation email (e.g. not prior to REC Favourable 
Opinion, MHRA Clinical Trial Authorisation etc., as 
applicable). If the submitted amendment included the 
addition of a new NHS organisation in England, the addition 
of the new NHS organisation is also approved and should 
be set up in accordance with HRA Approval processes (e.g. 
the organisation should be invited to assess and arrange its 
capacity and capability to deliver the study and confirm 
once it is ready to do so). 
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Long list of genes from family NNO4 
 
 – long candidate gene list (variants detected with high or moderate 
functional impact) 
For family NN04, variants in protein coding regions of 442 genes co-
segregate with cholesteatoma, for dominant model considered by Dan 
Swan. 
 How many of these are variants in a European cohort with 
minor allele frequency of  
< 20 % 
Het only VCF (protein coding only)  
2133 variants (none novel)  
http://grch37.ensembl.org/Homo_sapiens/Tools/VEP/Result
s?db=core;field1=IMPACT;from=1;operator1=is;size=792;tl=
1n0cxdw0LGzhEIaH-3899140;to=792;value1=MODERATE 
< 10 % 
Het only VCF 
1478 variants (see Moderate impact 
variants)  
http://grch37.ensembl.org/Homo_sapiens/Tools/VEP/Result
s?db=core;tl=xFEKEjPnE8AKdd8G-3899252 
< 5 % 
Het only VCF 
1158 variants 
http://grch37.ensembl.org/Homo_sapiens/Tools/VEP/Result
s?db=core;tl=t2A576y7jxPzPgWM-3899271 
1. FHAD1 
2. CLCNKA 
3. ATP13A2 
4. ALPL 
5. HSPG2 
6. LACTBL1 
7. MYOM3 
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8. CSMD2 
9. EPHA10 
10. MACF1 
11. COL9A2 
12. SPATA6 
13. COA7 
14. PODN 
15. C8A 
16. C8B 
17. INADL 
18. L1TD1 
19. PDE4DIP 
20. BCL9 
21. KIAA1614 
22. TSEN15 
23. PPFIA4 
24. PIK3C2B 
25. EPRS 
26. HLX 
27. HHIPL2 
28. CAPN8 
29. CAPN2 
30. DNAH14 
31. TMEM63A 
32. TRIM11 
33. URB2 
34. MCM10 
35. FRMD4A 
36. PIP4K2A 
37. GAD2 
38. ANKRD26 
39. PTCHD3 
40. ANXA11 
41. AL359195.1 
42. SH2D4B 
43. IFIT2 
44. PNLIPRP3 
45. GRK5 
46. BAG3 
47. BTBD16 
48. DMBT1 
49. CHST15 
50. MKI67 
51. LGR4 
52. TCP11L1 
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53. KIAA1549L 
54. SHANK2 
55. PAAF1 
56. SORL1 
57. OR6T1 
58. OR8B12 
59. PANX3 
60. CDON 
61. A2ML1 
62. PZP 
63. CLEC2D 
64. CLEC1B 
65. ART4 
66. MGP 
67. CASC1 
68. IFLTD1 
69. OVCH1-AS1 
70. OVCH1 
71. OR9K2 
72. OR6C74 
73. OR6C1 
74. GLS2 
75. HELB 
76. BEST3 
77. MYRFL 
78. KRR1 
79. OTOGL 
80. PTPRQ 
81. RASSF9 
82. CEP290 
83. PLXNC1 
84. CCDC41 
85. VEZT 
86. C12orf55 
87. OAS3 
88. GOLGA3 
89. ZNF268 
90. GTF3A 
91. USPL1 
92. ZAR1L 
93. N4BP2L2 
94. KL 
95. SCEL 
96. UGGT2 
97. LIG4 
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98. OR4N2 
99. OR11H6 
100. TEP1 
101. RNASE4 
102. OR10G3 
103. TRAV12-2 
104. OR6J1 
105. HEATR5A 
106. C14orf182 
107. MAP4K5 
108. FERMT2 
109. KTN1 
110. AL391152.1 
111. SYNE2 
112. PLEKHH1 
113. SLC39A9 
114. ABCD4 
115. SAMD15 
116. GALC 
117. NRDE2 
118. TRIP11 
119. ATXN3 
120. SERPINA6 
121. NPAP1 
122. EMC7 
123. FSIP1 
124. INO80 
125. MGA 
126. BP1 
127. ZNF106 
128. SEMA6D 
129. SEMA6D 
130. ADPGK 
131. PML 
132. PEAK1 
133. CHRNA5 
134. ADAMTS7 
135. C15orf40 
136. WDR73 
137. ZNF592 
138. ACAN 
139. TICRR 
140. WDR93 
141. C15orf32 
142. RGMA 
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143. TEKT5 
144. PRM3 
145. CTD-3088G3.8 
146. KNOP1 
147. POLR3E 
148. USP31 
149. PALB2 
150. TNRC6A 
151. PRR14 
152. FBXL19 
153. ZNF267 
154. IGHV3OR16-13 
155. ABCC12 
156. NLRC5 
157. CDH11 
158. FAM65A 
159. ACD 
160. NRN1L 
161. SLC12A4 
162. CDH3 
163. CDH1 
164. NPIPB15 
165. GLG1 
166. RFWD3 
167. NUDT7 
168. PKD1L2 
169. CMIP 
170. MTHFSD 
171. MAP1LC3B 
172. CTU2 
173. GALNS 
174. ZNF276 
175. WDR81 
176. SMG6 
177. SGSM2 
178. AC006435.1 
179. OR1A2 
180. TRPV3 
181. TRPV1 
182. SHPK 
183. TRPV1 
184. GGT6 
185. VMO1 
186. TMEM102 
187. DNAH2 
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188. KDM6B 
189. DNAH9 
190. NCOR1 
191. MPRIP 
192. MYO15A 
193. AKAP10 
194. CCDC144NL 
195. KIAA0100 
196. ATAD5 
197. SYNRG 
198. PSMD3 
199. KRT28 
200. KRT39 
201. KRT40 
202. KRT33B 
203. KRT14 
204. ACLY 
205. AOC3 
206. B4GALNT2 
207. ITGA3 
208. MYCBPAP 
209. COG1 
210. C17orf80 
211. TTYH2 
212. LLGL2 
213. MYO15B 
214. Sep-09 
215. TMC6 
216. DNAH17 
217. CANT1 
218. RNF213 
219. OGFOD3 
220. HEXDC 
221. C17orf62 
222. RAB40B 
223. USP14 
224. C18orf56 
225. NDC80 
226. TGIF1 
227. APCDD1 
228. CIDEA 
229. ZNF521 
230. TAF4B 
231. ASXL3 
232. C18orf21 
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233. MOCOS 
234. FHOD3 
235. PCSK4 
236. TMPRSS9 
237. TBXA2R 
238. PLIN4 
239. RFX2 
240. ACTN4 
241. ECH1 
242. AC104534.3 
243. ECH1 
244. AHSA2 
245. VPS54 
246. SLC1A4 
247. APLF 
248. ARHGAP25 
249. GKN2 
250. FIGLA 
251. MPHOSPH10 
252. MOGS 
253. MRPL53 
254. TTC31 
255. LBX2 
256. DNAH6 
257. CD8B 
258. ANKRD36C 
259. STARD7 
260. ITPRIPL1 
261. NCAPH 
262. FAM178B 
263. VWA3B 
264. IL1RL1 
265. HOXD1 
266. PDE11A 
267. PRKRA 
268. TTN 
269. CCDC141 
270. COL5A2 
271. MFSD6 
272. SPATS2L 
273. AC079354.1 
274. STK36 
275. TTLL4 
276. PRKAG3 
277. CCDC108 
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278. COL4A3 
279. SPHKAP 
280. SP110 
281. SP110 
282. ITM2C 
283. SEL1L2 
284. SCP2D1 
285. CSTL1 
286. BPIFB4 
287. DHX35 
288. ZHX3 
289. PCK1 
290. ZBP1 
291. C20orf85 
292. ZNF831 
293. LAMA5 
294. SRMS 
295. HELZ2 
296. RTEL1 
297. TMPRSS3 
298. KRTAP10-5 
299. KRTAP10-12 
300. PCNT 
301. TRIOBP 
302. KDELR3 
303. NDUFA6 
304. TCF20 
305. PNPLA3 
306. ATXN10 
307. MOV10L1 
308. TUBGCP6 
309. KLHDC7B 
310. IRAK2 
311. PPARG 
312. CAND2 
313. C3orf20 
314. FGD5 
315. CX3CR1 
316. ENTPD3 
317. CCRL2 
318. LRRC2 
319. TDGF1 
320. PRSS45 
321. ZNF589 
322. SPINK8 
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323. USP19 
324. FRMD4B 
325. ZNF717 
326. DHFRL1 
327. CRYBG3 
328. OR5H2 
329. OR5K1 
330. COMMD2 
331. FAM194A 
332. LEKR1 
333. IFT80 
334. RP11-432B6.3 
335. IFT80 
336. SPATA16 
337. RTP4 
338. ATP13A5 
339. LSG1 
340. XXYLT1 
341. REST 
342. UGT2B4 
343. AMTN 
344. C4orf26 
345. TMEM150C 
346. IBSP 
347. HERC5 
348. PYURF 
349. CCSER1 
350. SMARCAD1 
351. CLDN24 
352. ARHGEF28 
353. SPZ1 
354. VCAN 
355. CCNH 
356. KIAA0825 
357. ANKRD32 
358. RHOBTB3 
359. ERAP1 
360. LNPEP 
361. SLCO6A1 
362. ZRSR1 
363. REEP5 
364. YTHDC2 
365. GABRP 
366. SIMC1 
367. CLK4 
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368. ZNF454 
369. ZFP62 
370. BTNL9 
371. TRIM7 
372. BTN3A3 
373. HIST1H1B 
374. CCHCR1 
375. PRRC2A 
376. PPT2 
377. PPT2-EGFL8 
378. EGFL8 
379. NOTCH4 
380. C6orf10 
381. HLA-DOB 
382. TAP2 
383. PSMB8 
384. BRD2 
385. HLA-DOA 
386. KIFC1 
387. PNPLA1 
388. KCTD20 
389. CAPN11 
390. TDRD6 
391. EFHC1 
392. FKBP1C 
393. IRAK1BP1 
394. PHIP 
395. UBE3D 
396. DOPEY1 
397. PGM3 
398. NT5E 
399. GABRR1 
400. MANEA 
401. MMS22L 
402. AKAP12 
403. CCDC170 
404. SYNE1 
405. OPRM1 
406. SCAF8 
407. GPR146 
408. GPER1 
409. IQCE 
410. C1GALT1 
411. VWDE 
412. MEOX2 
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413. MACC1 
414. ABCB5 
415. STK31 
416. CPVL 
417. NPSR1 
418. TRGC2 
419. HECW1 
420. ZMIZ2 
421. TNS3 
422. ABCA13 
423. LANCL2 
424. ZNF727 
425. ZNF679 
426. ZNF680 
427. TYW1B 
428. PCLO 
429. LRRC61 
430. KMT2C 
431. ANK1 
432. RB1CC1 
433. TRPA1 
434. SBSPON 
435. STAU2 
436. ZFAT 
437. GPR144 
438. AL590708.2 
439. VAV2 
440. C9orf141 
441. CACNA1B 
442. RBMXL3 
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